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Hepatocellular carcinoma (HCC) is the third most common cause of death from 
cancer worldwide due to the challenges in both its diagnosis and treatment. 
According to recent studies, HCC tumors, like many other solid tumors are initiated 
and maintained by a subpopulation of cells called “cancer stem cells (CSCs)” or 
"tumor-initiating cells (TICs)". HCC stem cells can be identified by the expression of 
cardinal CD markers such as CD133 (Prominin-1) and epithelial cell adhesion 
molecule (EpCAM). This study primarily focuses on the investigation of 
mechanisms involved in the generation of HCC stem cell sub-population using a 
panel of 15 HCC cell lines. Preliminary data indicates that four cell lines (27%) 
display CD133
+
 stem cell populations at frequencies ranging from 8 to 90% when 
tested by flow cytometry. Among these CD133 positive cell lines, two isogenic cell 
line with different positivity levels prompted us to focus on two specific cell lines;, i) 
parental HepG2 cell line and its clone, which was transfected with four copies of 
hepatitis B virus (HBV), namely ii) HepG2-2215. With tumorigenicity assay induced 
in atymic nude mice, data revealed that HepG2-2215 that had higher CD133
+
 ratio, 
showed higher and rapid tumor formation than parental HepG2 that had much lower 
CD133
+
 sub-cellular proportion. Microarray analyses were performed to underpin 
the mechanisms of in CD133
+
 cell number variations of these two cell lines. Our 
initial findings suggested that FGFR signaling pathway might have played a role. To 
investigate these findings, FGFR signaling pathway was inhibited via potent inhibitor 
as well as knock down with siRNA. However, preliminary data did not indicate these 
presumptions and further studies are needed to clarify the relationship between 
FGFR signaling and CSC formation in HCC. Also, role of suppressive 
oligodeoxynucleotide (ODN) was studied to see the effects of suppression of DNA-
driven immunostimulation. Findings showed that suppressive ODN decreased 
CD133 levels, which indicates the difference between these two cell lines may arise 
from the HBV transfection of HepG2-2215 cell line which can produce HBV 
particles. However, further investigation is needed to understand the relationship 
between HBV infection and CSC population in HCC.  
 
Keywords: hepatocellular carcinoma, cancer stem cells, CD133, EpCAM, Wnt, TGF-
, FGFR 
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ÖZET 
KARACİĞER KANSERİNDEKİ KANSER KÖK HÜCRELERİNİN 
BELİRLENMESİ 
Merve Deniz Abdüsselamoğlu 
Moleküler Biyoloji ve Genetik Yüksek Lisansı 
Danışman: Prof. Dr. İhsan Gürsel 
Eş Danışman: Prof. Dr. Mehmet Öztürk 
Haziran 2014, 96 Sayfa 
 
Hepatosellüler karsinom (HSK) teşhis ve tedavi sürecindeki sıkıntılardan dolayı, 
dünyada, kansere bağlı ölümlerde ilk üç sırada yer almaktadır. Yapılan son 
çalışmalara göre, HSK tümörleri, diğer birçok solid tümör gibi, “kanser kök hücreleri 
(KKH)” ya da “ kanser başlatan hücreler (KBH)” olarak adlandırılan hücreler 
tarafından başlatılır ve tümörün devamlılığı bu hücrelere bağlıdır. HSK kök hücreleri 
bazı CD markörlerinin ifadesi ile tanınabilir, CD133 (Prominin-1) ve EpCAM de bu 
markörlerden biridir. Bu çalışma genel olarak, HSK kök hücrelerinin oluşmasında 
yer alan mekanizmaları, 15 adet HSK hücre hattından oluşan bir panelde incelemeye 
odaklanmıştır. Ön çalışmalarımız, akış sitometresi deneylerinde, sadece dört hücre 
hattının (27%), 8-90% olarak değişen oranlarda CD133+ kök hücre topluluğuna sahip 
olduğunu göstermiştir. Bu CD133 pozitif hücre hatları arasında iki izojenik hücre 
hattı, farklı pozitivite seviyeleri nedeniyle odaklanılmıştır,, i) parental hücre hattı 
HepG2 ve hepatit B virüsünün (HBV) dört kopyasıyla transfekte edilmiş olan klonu, 
ii) HepG2-2215. Atymic çıplak farelerde yapılan tümör gelişimini deneyi ile yüksek 
CD133+ hücre oranına sahip HepG2-2215, daha az CD133+ hücre sayısına sahip 
HepG2’den daha hızlı ve çabuk tümör oluşumu göstermiştir. Mikro-dizi analizi 
yapılarak bu hücre hatlarının CD133 + hücre sayıları farkı altında yatan 
mekanizmalarını keşfetmek amaçlanmıştır. İlk bulgularımız FGFR sinyal yolağının 
role sahip olabileceğini düşündürmektedir. Bu bulguları test etmek için FGFR yolağı 
güçlü bir inhibitör ve siRNA muamelesi ile susturulmuştur. Ancak, ilk veriler bu 
düşüncelerimizi desteklememiştir. Bu yüzden HSK'da FGRF yolağı ve KKH 
oluşumu arasındaki ilişkiyi netleştirmek için başka çalışmalara ihtiyaç vardır. Ayrıca, 
DNA güdümlü immün uyarıcı etkileri susturan, baskılayıcı oligodeoxynucleotide 
(ODN) rolü DNA çalışılmıştır. Bulgular baskılayıcı ODN muamelesinin CD133 
oranlarını düşürdüğünü göstermiş. Sonuçlar, bu iki hücre hattının farklı CD133 
positivite oranlarına sahip olmasının sebebinin HepG2-2215 hücre hattının HBV 
transfekte olup, HBV partikül oluşturmasından dolayı olabileceğine işaret etmiştir. 
Ancak, HSK’daki KKH nüfusu ile HBV ilişkisini anlamak için daha fazla araştırma 
gereklidir. 
Anahtar sözcükler: hepatosellüler karsinom, kanser kök hücreleri, CD133, EpCAM, 
TGF-, FGFR 
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CHAPTER 1 
 
 
INTRODUCTION 
 
 
1.1 Hepatocellular Carcinoma 
 
1.1.1 Epidemiology of Hepatocellular Carcinoma 
 
Liver is the largest internal organ in the body and performs many essential roles in 
digestion, metabolism, immunity and so on [1]. Cancers originate in the liver are 
called liver cancer. Hepatocellular carcinoma (HCC) is the most common type of 
primary liver cancers with 80-90% of occurrence in all cases [2]. It is the sixth most 
commonly occurring cancer and ranked as the third leading cause of cancer-related 
deaths worldwide [3]. Unfortunately, there are limited treatment options, such as 
tumor resection, liver transplantation, radiofrequency ablation, and because of high 
number of patients diagnosed with the disease at advance stage, approximately one 
third of them are eligible for treatments with 14% overall 5-year survival rate [3, 4]. 
With age, occurrence rate of HCC increases greatly with the highest prevalence 
among the population over age of 65 [5]. In addition to the age, sex is a significant 
factor with a higher occurrence ratio in men. 
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1.1.2 Aetiologies and Risk Factors of Hepatocellular Carcinoma 
 
Many intrinsic and extrinsic factors interact with each other at molecular level which 
causes hepatocarcinogenesis [4, 6]. Thus, aetiological factors leading to HCC are 
complex. Among them, infection with hepatitis B (HBV) and C virus (HCV) 
contributes to 70% of all cases [7]. Beside these factors, alcohol abuse, aflatoxin 
contaminated food consumption, immune related factors, metabolic diseases, such as 
diabetes and obesity, are also other risk factors of HCC [2]. Although all these 
factors are linked to the incidence of HCC, their efficacy and prevalence depend on 
the geographical conditions. While HBV infection is the major factor in most Asian 
and African countries, in Europe and United States, HCV infection is the primary 
reason for the incidence of HCC [8]. Also, while alcohol abuse is a more common 
factor in western countries, dietary aflatoxin consumption is more common in South 
China and Africa [7].  
 
1.1.2.1 Viral Hepatocarcinogenesis  
 
Chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) is the 
leading etiology for the HCC [9]. And the incidence of HCC parallels with the 
geographic distribution of these infections. 80-90% of HCC patients were infected 
with HBV and HCV that promote cirrhosis, initially [10]. HBV and HCV are two 
unrelated viruses that target liver and reside in hepatocytes [11]. HBV is a small 
DNA virus, that belongs to hepadnaviridae family and its transmission occurs via 
contaminated blood products or sexual contact [9]. The virus has 3.2 kb genome 
consisting of four overlapping open reading frames. Previous studies suggested that 
chronic HBV infection might increase the risk of HCC up to 100 fold [9, 10]. 
Integration of HBV DNA can induce chromosomal instability and it allows 
persistence of the virus [12]. Recent data suggested that HBV is targeting several 
gene families, such as the telomerase-encoding gene, genes involved in calcium 
homeostasis, and thus, the expression of some of these target genes are deregulated 
[12]. Hepatitis B virus X protein (HBx) is 154 amino acid viral protein that has vital 
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roles in HBV infection, replication and it is also linked to liver carcinogenesis (Fig. 
1.1) [9]. The oncogenic potential of HBx can be categorized into four groups; trans-
activation or repression of cell survival and proliferation genes, interaction with 
proteins that have roles in cellular response to oncogenic stress, activation of cell 
survival signaling pathways and epigenetic changes including DNA methylation, 
histone modification and microRNA expression [9, 12].  
 
Figure 1.1: Different targets of HBx protein. Adapted from [12]. 
On the other hand, hepatitis C virus is a positive-sense, enveloped, single-stranded 
RNA virus, a member of the Hepacivirus genus of the Flaviviridae family [13]. Its 
genome is 9.6 kb in length and it is associated with a 15- to 20-fold increase in risk 
for HCC [10]. HCV infection induces several cellular responses, such as ER stress 
and UPR, autophagy, apoptosis, cell cycle arrest and DNA damage, mitogenic 
signaling, and PI3K pathway [13].  
Thus, HBV and HCV infections together are the strongest risk factors for developing 
HCC by changing gene expression in liver [11]. These changes includes alterations 
in DNA methylation, changes in miRNA expression profiles and the constitutive 
activation of numerous signal transduction pathways [9].  
 
1.1.2.2 Role of Alcohol in Hepatocarcinogenesis 
 
Chronic heavy alcohol consumption is closely associated with hepatocarcinogenesis. 
Alcohol causes changes in liver structure, especially in hepatocytes [14]. In ethanol 
4 
 
metabolism in liver, ethanol is oxidized by cytochrome P450 2E1 (CYP2E1), 
generating reactive oxygen species (ROS) [15]. ROS are the most potent agents that 
can alter DNA methylation patterns in liver [15]. Also, ROS play major role in 
telomere shortening and favor mutations in oncogenes [2, 14]. Also, chronic alcohol 
ingestion is associated with enhanced inflammation causing activated monocytes 
which generates pro-inflammatory cytokines [14]. These cytokines activate Kupffer 
cells to produce chemokines that have opposite effects on hepatocyte survival [16]. 
 
1.1.2.3 Role of Aflatoxin in Hepatocarcinogenesis 
 
Aflatoxins are major mycotoxins that are naturally occurring metabolic byproducts 
of Aspergillus flavus and Aspergillus parasiticus [17]. Aflatoxins can be found 
ubiquitously in staple foods, including maize, rice, and ground nuts [18]. Aflatoxin 
contamination of crops usually occurs in the regions where food drying and storage 
facilities are not in optimal conditions. They are the most common food-borne risk 
factor [17]. Exposure to aflatoxin B1 contamination of foods correlates well with the 
incidence of HCC. The effect of aflatoxin B1 on hepatocarcinogenesis is linked to 
the mutation caused by aflatoxin exposure in AGG to AGT transversion mutation at 
codon 249 of the p53 gene [19]. 
 
1.1.2.4 Other Factors Inducing Hepatocarcinogenesis  
 
Other than these factors associated with HCC, there are other risk factors 
implemented to play a role in hepatocarcinogenesis. Diabetes is one of those factors 
that is thought to promote the onset of HCC with an effect of 2-3 fold increase [20]. 
Obesity is also a risk factor with diabetes and the reason for this predisposition is 
possibly caused by insulin resistance that is reduced insulin sensitivity and as a 
consequence, increased secretion; and accumulation of free fatty acids [21]. Thus, 
liver fibrosis develops through dysfunctional effects on liver homeostasis. 
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In addition to diabetes, non-alcoholic steatohepatitis and non-alcoholic fatty liver 
diseases are likely to promote hepatocarcinogenesis by contributing liver fibrosis and 
development of cirrhosis [22]. Also, hereditary heamochromatosis, a common 
genetic disorder, is linked to hepatocarcinogenesis because of excessive iron 
absorption in hepatocytes [23]. Another inherited genetic disorder which promotes 
HCC development is alpha1-antitrypsin deficiency. This disease causes antitrypsin 
polymers formation in liver and as a consequence hepatocyte fatality triggering 
cirrhosis [24].  
 
1.1.3 Molecular Pathogenesis of Hepatocellular Carcinoma 
 
Molecular pathogenesis of HCC is rather complex including different risk factors and 
modulations, such as mutations, altered pathways, epigenetic changes, genetic 
changes and chromosomal aberrations (Fig. 1.2) [2]. Accumulation of these changes 
leads to neoplastic state in normal, non-cirrhotic and cirrhotic-livers. Actually basis 
of hepatocarcinogenesis is damaged hepatocytes that start proliferating and 
regenerating in high frequencies. This increased regeneration activity causes 
cirrhosis, and then dysplasia, and finally HCC [3]. 
 
Figure 1.2: Key signal transduction pathways involved in pathogenesis of HCC. 
Adapted from [25]. 
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Transition from normal liver to HCC liver is a multistep process that starts from 
genetic changes in cirrhotic liver which proceeds into hepatocarcinogenic liver with 
accumulating changes in the liver [26]. These changes includes mutations that cause 
genetic alterations, aberrant expression of cellular proteins, overexpression of 
oncogenes, inhibition of tumor suppressors, and molecules such as microRNAs and 
various cellular proteins [27]. There are number of critical signaling pathways 
activated in HCC as well as mutations that inactivates tumor suppressors, such as 
p53, Rb1, CDKN2A, IGF2R, PTEN; and activates oncogenes like -catenin, Axin1, 
PI-3-kinase and K-ras [25]. In the initial steps of HCC, HBV/HCV infections, 
alcoholic liver cirrhosis, and amplified signaling pathways, such as transforming 
growth factor alpha and insulin-like growth factor 2, boosts hepatocyte proliferation. 
These initial steps cause oncogenic activation, instable chromosomes and DNA 
rearrangements [27]. Further DNA damages induced by oxidative stress and chronic 
inflammation occur in hepatocytes [25]. Activation of survival and proliferation 
pathways along with uncontrolled telomerase activity provides unlimited 
proliferative capacity for these transformed cells [26].  
 
1.1.4 Genetics of Hepatocellular Carcinoma  
 
Initial studies showed that HCC is highly associated with genetic aberrations, 
chromosomal abnormalities and chromosomal instability. Common alterations 
include chromosomes 1q, 5, 6p, 7, 8q, 17q and 20 with chromosomal gains whereas 
1p, 4q, 6q, 8p, 13q, 16, 17p and 21 are deletion sites [28]. On the other hand, HBV 
infection often results in integration into host genome which may have cis and trans 
effects. It is observed that HBV genome integration generally take place within or 
upstream of TERT (telomerase reverse transcriptase) gene which is the most likely 
reason of increased telomerase activity [2]. There are a few somatic mutations that 
are associated with hepatocarcinogenesis. TP53 was the first mutated gene 
discovered in HCC [29]. TP53, CTNNB1 which encodes for -catenin and AXIN1 
genes display small deletions or point mutation while CDNK2A gene exhibits 
homozygous deletions and epigenetic silencing [28]. 
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1.2 Cancer Stem Cells 
 
In the traditional way, cancer initiation and the progression was explained by the 
stepwise process of accumulation of genetic and epigenetic changes [30]. This way, 
cell enters a dedifferentiation state where it gains uncontrollable proliferative ability 
and tumor formation ability. Thus, this stochastic model suggests that once a random 
mutation and subsequent clonal selection have taken place, each cell would be equal 
in terms of forming a new tumor. However, findings in cellular hierarchy and tumor 
heterogeneity have led to a new model which proposes that only a subpopulation of 
cells have the ability to self-renew, differentiate and regenerate [31]. This model is 
the cancer stem cell (CSC) hypothesis which suggests that tumors are organized 
similarly to normal tissues [32]. Cancer stem cells have the similar capabilities as 
stem cells, such as self-renewal, giving rise to heterogeneous progeny and dividing in 
unlimited fashion [33]. CSC hypothesis has been recently validated with various 
experiments including identification of stem cell marker positivity with hierarchy, 
serial in vitro clonogenic growth, and in vivo tumorigenicity [33]. These experiments 
showed that tumor can be initiated from a single cell, cancer stem cell that is also 
names as tumor initiating cell (TIC) [30]. The first data demonstrating the existence 
of CSCs was obtained from acute myeloid leukemia (AML) [32]. Studies showed 
that leukemia stem cells from AML patients are both self-maintaining and can 
reconstitute all different phenotypes in consistence with CSC model. Meanwhile, 
similar observations were made in different types of cancers, including breast cancer 
and glioma [32]. 
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1.2.1 Cancer Stem Cells in HCC and Possible CSC Markers 
 
Like other solid tumors, HCC is thought to contain cancer stem cells (CSCs) as a 
distinct subpopulation of tumor cells that are capable of tumor relapse and metastasis 
due to the their abilities to self-renew, differentiate and give rise to a new tumor in 
local and distant sites [34]. CSCs are identified as tumor initiating properties which 
inoculations of these cells have continuous cell growth in serial transplantation [35]. 
These cells are very few in the tumors while the rest of the tumor bulk cannot initiate 
tumor growth, which are considered to be non-tumorigenic [35].  
The first treatment option for HCC is either liver transplantation or surgical 
resection. However, most HCC patients are at advanced stages which make them 
inoperable [36]. Other treatment option is chemotherapy but HCC remains largely 
incurable because of late presentation and tumor recurrence [37]. Also, HCC has 
chemotherapy-resistant nature with high recurrence rate. The current existing 
therapies against HCC are generally targeting tumor bulk rather than CSCs [36]. 
Thus, remaining CSCs lead to re-growth of the tumor. So, isolating and targeting 
CSCs is very important for better treatment options. A number of molecular markers 
have been identified for CSCs in HCC, including CD133, epithelial cell adhesion 
molecule (EpCAM), CD90, CD44, CD13, CD24, OV6, granulin-epithelin precursor 
(GEP), and Delta-like 1 homolog (DLK1) [36]. 
Table 1.1: List of CSC markers in HCC and their possible functional roles. Adapted 
from [36] 
Marker Possible Functional Role 
CD133 Self-renewal, tumorigenicity, chemo-resistance and 
invasiveness 
EpCAM Invasiveness, self-renewal, and tumor formation 
CD90 - 
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CD44 Tumor formation, chemo-resistance and metastasis 
CD13 Self-renewal, cell proliferation, and tumor formation 
CD24 Tumor formation, self-renewal, chemo-resistance, and 
metastasis 
OV6 - 
GEP Self-renewal, chemo-resistance, tumor growth 
DLK1 Cell proliferation, self-renewal, tumor formation and 
tumor growth 
 
CD90 (Thy-1) is 25-37 kDa glycosylphosphatidylinositol-anchored cell surface 
protein [34]. It has been considered as a marker for various stem cells including CSC 
in HCC and recent data suggests that there is a positive correlation between CD90 
expression with self-renewal, tumorigenicity and metastasis [34, 36]. Meanwhile, 
CD44 has been associated with various cancer functions, especially metastasis [36]. 
It is a cell surface glycoprotein and it acts as a receptor for hyaluronic acid and CD44 
is a marker in combinations with other CSC markers [34]. CD13 is a newly identified 
functional marker which can be used to identify dormant liver CSCs resistant to 
treatments [35]. CD24 is a mucin-like cell surface glycoprotein that has been linked 
to self-renewal and chemo-resistance [34]. OV6 is a marker for oval cells and it is 
used widely as hepatic stem cell marker [36]. GEP is a hepatic oncofetal protein that 
is expressed in fetal liver and associated with recurrence of HCC [36]. Finally, DLK1 
is a hepatic stem cell marker that is also expressed in fetal liver. 
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1.2.2 Prominin 1 (CD133)  
 
CD133 is a member of the prominin family of pentaspan transmembrane 
glycoprotein that is also known as Prominin 1 (PROM1) [38]. Even though its 
specific function and ligands are still unknown, CD133 is firstly found hematopoietic 
stem/progenitor cell marker [38]. CD133 is found in various cancer types, such as 
brain, prostate, pancreas, colon and liver as CSC marker [34]. Previously, it has been 
shown that during early liver regeneration, CD133 is up-regulated in liver tissue [36]. 
Functional studies with CD133
+
 cell fraction isolated from Huh7 cell line 
demonstrated that these cells have significantly greater tumorigenicity potential in 
vitro and in vivo, than CD133
-
 cells [39]. It has been also found that CD133
+
 cells 
have higher colony-forming efficiency and proliferation ability [37, 38]. Further 
studies revealed that CD133
+
 cells are more chemo-resistant and radio-resistant 
because of preferential activation of certain survival pathways, such as AKT/PKB, 
BCL-2 and MAPK/PI3K pathways [36]. A recent study showed that when compared 
to its CD133
-
 counterparts, CD133
+
 cells showed higher expression of stem cell 
associated genes ( Bmi-1, Notch, Sox2, Oct 4, Nanog, -catenin, Smo, Nestin, 
ABCG2 and ABCB1) as well as they have the ability to form undifferentiated tumor 
spheroids [38]. 
 
1.2.3 EpCAM (CD326) 
 
Epithelial cell adhesion molecule EpCAM (murine CD326) is a type I 
transmembrane glycoprotein with a large extracellular, a single transmembrane and a 
short intracellular domain [40]. It is known to be expressed in almost all of 
carcinomas while it is also expressed in embryonic liver, bile duct epithelium and 
proliferating bile ductules in cirrhotic liver [34]. Recent findings suggest a role for 
EpCAM as an early biomarker for HCC because of its high expression in 
premalignant hepatic tissues [34]. EpCAM
+
 HCC cells have been shown to possess 
ability of self-renewal, differentiate and initiate tumors [36]. EpCAM plays a role in 
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cell proliferation, migration and mitogenic signal transduction. EpCAM also has 
been shown that it is a direct transcriptional target for Wnt/-catenin signaling 
pathway [39, 41]. Further studies with microarray analysis with primary HCC tissue 
demonstrated that EpCAM+ HCC was associated with gene signature and the 
molecular pathway of hepatic progenitor cells. Meanwhile EpCAM- HCC cells were 
linked to mature hepatocytes [37].  
 
1.3 Signaling Pathways in CSCs 
 
During hepatocarcinogenesis, two main pathogenic mechanisms are observed. First 
one is cirrhosis associated with hepatic regeneration after tissue damage caused by 
several reasons, such as exposure to toxins, viral infections or metabolic influences, 
while the other mechanism is the occurrence of mutations in single or multiple 
oncogene or tumor suppressors [42]. In HCC, many major signaling pathways 
implicated, including Wnt/-catenin, PI3K/AKT1/mTOR, RAF/MKK1/MAPK3, 
IGF-1, HGF/c-MET and TGF- [42]. Interestingly, many of these pathways are 
known to be involved in stem cell maintenance self-renewal and pluripotency, such 
as MET, Hedgehog, MYC, p53, EGF, Wnt/-catenin, TGF-, etc [41]. Many of 
these signaling pathways are also found in CSCs which also suggest that these 
pathways should be investigated in HCC CSCs. 
 
1.3.1 Wnt Pathway 
 
The Wnt pathway is a highly conserved signaling pathway whose first member was 
identified in fruit fly [43]. The Wnt family consists of 19 Wnt ligands identified and 
the intracellular signaling is maintained via two different pathways; “canonical” and 
“non-canonical” [43]. The canonical Wnt pathway is activated by the binding of Wnt 
ligands to the transmembrane Frizzled receptor and its co-receptor LRP 5 or 6, and 
then, scaffolding protein Dishevelled (Dvl) is recruited. This stabilizes destruction 
complex composed of APC, AXIN1, GSK3 and CSNK1A1 which normally 
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phosphorylates -catenin leading to its ubiquitination and degradation [32, 44]. Thus, 
stabilized b-catenin translocated to nucleus in order to regulate transcription with 
TCF/LEF complex [44]. Wnt signaling plays an important role in embryonic 
development, growth, survival, regeneration, and self-renewal as well as in tumor 
development. It has been shown that several Wnt ligands were expressed by various 
liver cells, and Wnt/-catenin pathway plays a crucial role in prenatal development, 
hepatic fate specification of stem cells and liver organogenesis [43]. Aberrant 
activation of Wnt pathway is a factor participating HCC development [45]. Disrupted 
Wnt pathway by mutational or non-mutational events is observed in one third of all 
HCCs [46]. Activation of canonical Wnt pathway drives tumor formation in liver 
stem cells and the higher -catenin expression was found in HCC than non-tumor 
tissues [47]. The Wnt pathway also plays a crucial role in regulating stem/progenitor 
cell expansion as well as the determination of self-renewal or differentiation [48]. 
The elevated expression of Wnt and its downstream mediators were found in 
CD133
+
 or EpCAM
+
 HCC cells which suggest that Wnt/-catenin signaling pathway 
is implicated in HCC CSCs [41]. 
 
1.3.2 Transforming Growth Factor (TGF)- Pathway 
 
Transforming growth factor (TGF)- superfamily consists of TGF-s, activins, 
inhibins, Nodal, bone morphogenic proteins (BMPs) and anti-Müllerian hormone 
(AMH) and regulates many cellular functions, including cell growth, differentiation, 
apoptosis, extracellular matrix (ECM) production, immunity and embryonic 
development [49]. Canonical TGF- pathway is activated via binding of TGF- 
ligand to the heteromeric receptor complex which phosphorylates receptor activated 
SMAD (R-SMAD) proteins. Activated R-SMADs together with SMAD4 translocates 
to nucleus to act as transcription factor complex [50]. TGF- signaling pathway has a 
role in cell cycle regulation, the immune system and apoptosis. In HCC, it plays a 
crucial role in inhibiting oncogenesis at an early stage by inducing apoptosis and 
activates autophagy in certain HCCs in order to suppress tumor formation [47]. On 
the other hand, dysregulation of TGF- signaling is associated with 
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hepatocarcinogenesis [51]. TGF- signaling pathway is involved in self-renewal, 
differentiation and carcinogenesis [52]. Also, TGF- co-operates with oncogenic 
RAS to activate nuclear -catenin, which causes neoplastic hepatocyte differentiation 
into immature progenitor cells and facilitates HCC recurrence [47]. Finally, TGF- 
plays a crucial role in maintenance of CSCs in HCC and it has been shown that lack 
of responsiveness to TGF- led to the generation of CSCs [41]. 
 
1.3.3 Fibroblast Growth Factor Receptor (FGFR) Signaling Pathway 
 
Fibroblast growth factor (FGF) superfamily consists of structurally related 
polypeptides where most of them function through fibroblast growth factor receptors 
(FGFRs) [53]. In humans, FGFs are encoded by 22 genes which are divided into 7 
subfamilies. FGFRs are transmembrane tyrosine kinase receptors and are activated 
by binding of FGF ligands [54]. Binding of FGFs to FGFRs activates downstream 
signaling, enabling trans-phosphorylation of tyrosines in the intracellular part of 
receptor and these phophorylated tyrosine residues act as docking sites for various 
adaptor proteins which promotes activation of different signaling pathways, 
including Ras/Raf/MAPK, PI3K signaling pathway [54]. Thus, FGFR signaling 
pathway promotes cell growth, epithelial-mesenchyme transition and survival [56]. 
FGFR2 isoform b (FGFR2-IIIb) is highly expressed in hepatocytes and plays a 
crucial role in liver homeostasis and regeneration [55]. Studies showed that 
alterations in FGFR signaling pathway could lead to cancer [54]. Some of the FGF 
ligands are up-regulated in HCC and have been shown to initiate autocrine growth 
stimulation, cell survival and neo-angiogenesis [57]. Moreover, some FGF ligands 
were associated with more aggressive behavior of malignant hepatocytes and this 
might involve Wnt signaling pathway as well [58].  
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1.4 Suppressive Oligodeoxynucleotides (ODNs) 
 
Normally, DNA is isolated via nuclear or mitochondrial membrane in eukaryotes, or 
by the cell wall in bacteria or the envelope in viruses. However, following a 
microbial infection or tissue damage, DNA can be released [59]. In this case, due to 
its high unmethylated CpG motif frequency, bacterial DNA can be recognized as 
“non-self” via TLR9 and trigger an innate immunity response. This CpG-driven-
immune activation can exacerbate inflammatory tissue damage, or increasing 
sensitivity to autoimmune diseases or toxic shock [60].  
On the other hand, some immune responses are designed to protect the host. Previous 
studies suggested that some antagonistic elements are present in the host DNA 
possibly to suppress DNA-driven immunostimulation [61]. Thus, these neutralizing 
or suppressive motifs can block CpG-mediated immune system selectively [62]. 
These suppressive motifs are rich in poly-G or –GC sequences, and surprisingly, 
optimal motifs are identical to telomere motifs (with a repeat of TTAGGG) [63]. It 
has been shown that suppressive oligodeoxynucleotide (ODN) (A151) inhibits the 
production of several pro-inflammatory cytokines and chemokines induced by 
bacteria [63]. So, in different autoimmune and inflammatory diseases, the effects of 
suppressive ODN (A151) have been studied. Over the last few years, suppressive 
ODN (A151) has been studied in cancer types, especially in cancers that 
inflammation plays a crucial role. It has been shown that suppressive ODN can be 
used in inflammation associated oncogenesis [64]. This observation was supported 
with other studies showing that suppressive ODN can improve the anti-proliferative 
effects of anticancer drugs [65]. Meanwhile another study showed that suppressive 
ODNs actually repress fibrosis and down-regulates stemness (Aydin, M. et al., 
unpublished data). 
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1.4 Aim of the Study 
 
Like other solid tumors, HCC has been shown to possess a small subpopulation of 
cancer stem cells that are responsible from initiation, maintenance and recurrence of 
tumor [36]. These cells also show the ability to self-renew, give rise to different 
phenotypes of cells which accomplish tumor heterogeneity and chemo- or radio-
resistance. After the initial treatment, these CSCs are the ones who resisted the 
therapy and provided the re-growth of tumor. Thus, the idea of targeting these cells 
might be a better therapeutic approach along with traditional treatment methods in 
order to achieve better cure rate for the disease. 
However, targeting these cells requires more knowledge on the characterization of 
cancer stem cells in HCC. Molecular mechanisms underlying the process of these 
transformed cells into cancer stem cells might be the direct targets of future treatment 
methods to reverse this transition or at least it might provide opportunity to make 
cancer stem cells more vulnerable to the current treatments. The outcomes of this 
study are expected to make contributions to the field of new therapeutic approaches 
for HCC.  
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CHAPTER 2 
 
 
MATERIALS AND METHODS 
 
 
2.1 MATERIALS 
 
2.1.1 General Laboratory Reagents 
 
Most of the reagents used in this research including Bradford reagent, haematoxylin, 
ethanol and methanol were purchased from Sigma-Aldrich (St. Louis, MO, USA) 
and Merck (Darmstadt, Germany). ECL+ blot detection kit and western blot 
membranes were purchased from Amersham Pharmacia Biotech Company. DMSO 
and Ponceau S were purchased from Applied Biochemia (Darmstadt, Germany). 
Fluorescent mounting medium was from Dako (Denmark). Nucleospin RNA II total 
RNA isolation kit and DNase I was from Macherey-Nagel (Duren, Germany). 
Collagenase type I was purchased from Sigma-Aldrich (C0130-500MG, St. Louis, 
MO, USA) and Fixative Medium A was bought from Invitrogen (GAS003, Carlsbad, 
CA, USA). 
 
2.1.2 Cell Culture Materials and Reagents 
 
Dulbecco’s modified Eagle’s medium (DMEM) and Roswell Park Memorial Institute 
(RPMI) 1640 medium and OptiMEM were purchased from GIBCO (Invitrogen, 
Carlsbad, CA, USA). Penicillin/streptomycin antibiotics, L-glutamine, trypsin-
EDTA, fetal calf serum (FCS) was also from GIBCO. All plastic materials used in 
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cell culture, such as tissue culture flasks, petri dishes, plates, cryovials were 
purchased from Corning Life Sciences Inc. (USA). Serological pipettes were from 
Costar Corporation (Cambridge, UK). RNAi Max was purchased from Invitrogen. 
 
2.1.3 Spectrophotometry 
 
Bradford based protein concentration measurements were done using 
spectrophotometer Beckman Du640 from Beckman Instruments Inc. (CA, USA).  
 
2.1.4 Antibodies 
 
In this study, there are numerous primary and secondary antibodies from various 
sources. Antibodies, their catalog numbers, and working dilutions are given below in 
Table 2.1.  
 
Table 2.1: Antibody list, catalog numbers and working dilutions  
Antibody Company and 
catalog number 
Western Blot 
Dilution 
Immunostaining 
Working 
Dilution 
Calnexin Sigma, C4731 1:5000 - 
α-tubulin Calbiochem, CP06 1:5000 - 
Anti-mouse-HRP Sigma, A0168 1:5000 - 
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Anti-rabbit-HRP Sigma, 6154 1:5000 - 
Anti-goat-HRP Abcam, ab6741 1:5000 - 
Anti-mouse/rabbit-
Alexa Fluor 488 
Invitrogen, A11034 - 1:750 (IF) 
Anti-mouse/rabbit-
Alexa Fluor 568 
Invitrogen, A11034 - 1:750 (IF) 
-actin Sigma, A5441 1:10000 - 
P-FGFR R&D Systems 8µg/mL - 
Sox9 Millipore, AB5535 1:1000 1:1500 (IF) 
HNF4 Santa Cruz 
Biotechnologies, sc-
6556 
1:300 1:150 (IF) 
Bek antibody Santa Cruz 
Biotechnologies, sc-
6930 
- 1:30 (Flow 
Cytometry) 
CD133 pure Miltenyi, 130-090-422 - 1:100 (IP, IF) 
CD133-APC Miltenyi, 130-090-826 - 1:30 (Flow 
Cytometry) 
EpCAM-FITC Miltenyi, 130-080-301 - 1:30 (Flow 
Cytometry) 
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Anti-acetylated--
tubulin 
Abcam, ab24610 1:2000 - 
Anti-Histone H3 Abcam, ab1791 1:5000 - 
Anti-acetyl-H4 Millipore, 06-866 1:5000 - 
 
2.1.4.1 Antibody Conjugation Kit 
 
Lightning-Link Atto488 Conjugation kit (733-0010) was purchased from Innova 
Biosciences. 
 
2.1.5. Immunoperoxidase Staining Reagent 
 
In immunoperoxidase staining experiments; DAKO EnVision+ System was used, 
DAKO (Glostrup, Denmark). 
 
2.1.6. Suppressive Oligodeoxynucleotide and Control Oligodeoxynucleotide 
 
All oligodeoxynucleotide (ODN) types used in this study listed in Table 2.2 with 
their working concentrations. 
Table 2.2: List of ODNs used in this study. 
Name Concentration 
A151 (suppressive ODN) 0.5 - 3µM 
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D35 flip 0.5 - 3µM 
 
Oligodeoxynucleotides (ODN) sequences given below were purchased from either 
Alpha DNA, (Canada) or NIH or USFDA CBER Core Facility (USA), or 
synthesized in the Biotherapeutic ODN Research Lab. Facility on a MerMade6 
Oligonucleotide synthesizer machine: 
 
A151              5’ TTAGGGTTAGGGTTAGGGTTAGGG 3’ 
D35 flip-         5’ ggTGCATGCATGCAGGGGgg 3’ 
 
2.2 SOLUTIONS AND MEDIA  
 
2.2.1 General Solutions 
 
10X Phosphate Buffered Saline (PBS) 80g NaCL, 2g KCl, 14.4g Na2HPO4, 2.4g 
KH2PO4 in 1 litre ddH2O 
Working dilution is 1X. 
 
10X Tris buffered saline (TBS) 12.9g Trisma base, 87.76g NaCL, in 1 litre 
ddH2O, pH is adjusted to 8.0 
Working dilution is 1X. 
 
2.2.2 Tissue Culture Solutions 
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DMEM/RPMI media  Complete medium contains 10% Fetal calf 
serum, 1% penicillin/streptomycin, 1% non-
essential amino acids, stored at 4   C  
Serum free DMEM/RPMI media 0.01% Fetal calf serum, 1% 
penicillin/streptomycin, 1% non-essential 
amino acids, 1mM Na2SeO3, stored at 4   C 
10X Phosphate buffered saline (PBS) 80g NaCL, 2g KCl, 14.4g Na2HPO4, 2.4g 
KH2PO4 in 1 litre ddH2O 
Working dilution is 1X, stored at 4   C 
 
2.2.2.1 Preparation of Wnt-3a and WIF1 
 
Reconstitute Recombinant Human Wnt-3a (R&D Systems, 5036-WN/CF) at 
200µg/mL in sterile 1X PBS. Working concentration is 250ng/mL. Reconstitute 
Recombinant Human WIF-1 (R&D Systems, 1341-WF/CF) at 200µg/mL in sterile 
1X PBS. Working concentration is 250ng/mL. 
 
2.2.2.2 Preparation of TGF-1 and anti-TGF1 antibody 
 
Reconstitute TGF-1 (R&D Systems, 240-B) at concentration of no more than 
10µg/mL in filter-sterilized 4mM HCl containing 1mg/mL bovine serum albumin to 
ensure complete recovery from glass surfaces. Working concentration is 5ng/mL. 
Reconstitute TGF-b1 antibody (monoclonal mouse IgG1, R&D Systems, Mab240) at 
0.5mg/mL in sterile 1X PBS. Working concentration is 5µg/mL. 
 
22 
 
2.2.2.3 Preparation of SU5402 
 
Reconstitute SU5402 (Santa Cruz Biotechnologies, sc-204308) at 1mM in sterile 
DMSO. Working concentrations between 2µM to 50µM were tired. 
 
2.2.3 Immunoperoxidase Solutions  
 
Acetone: methanol fixation reagent Acetone and methanol were mixed in 1:1 
ratio and stored at -20   C 
3% H2O2 solution Dilute 30% H2O2 with methanol and ddH2O. 
(For example, 3mL H2O2, 10mL methanol, 
and 17mL ddH2O) 
Immunoperoxidase blocking solution 10% FCS in 0.3% TritonX-100 in 1X PBS 
Washing solution 0.3% TritonX-100 in 1X PBS 
Antibody dissolved in  10% FCS in 0.3% TritonX-100 in 1X PBS 
DAB solution DAB chromogen and its substrate from 
Dako were used according to the 
manufacturer’s protocol 
 
2.2.4 Immunofluorescence Staining Solutions 
 
4% Formaldehyde It is prepared dissolving 50mL 40% 
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formaldehyde in 450ml ddH2O. 
4% Paraformaldehyde Dissolve 4g paraformaldehyde in 100mL 
ddH2O, heat at 130  C for 1 hour, cool before 
use 
Immunofluorescence blocking solution 10% FCS in 0.2% PBS-Tween 20 
Washing solution 0.2% PBS-Tween 20 
Antibody dissolved in  10% FCS in 0.2% PBS-Tween 20 
DAPI (4’,6-diamino-2-phenylindole) 0.1-1µg/ml working solution in PBS or 
ddH2O 
 
2.2.5 Sodium Deodecyl Sulphate (SDS) – Polyacrylamide Gel Electrophoresis 
(PAGE) and Immunoblotting Solutions  
 
In this study, tris-glycine gels and buffers were prepared manually according to a 
conventional protocol in our lab. To prepare 5% stacking gel, 30% acrylamide mix, 
1.0M Tris-HCl pH 6.8, 10% SDS, 10% ammonium persulphate and ddH2O were 
mixed in appropriate amounts. For the resolving gels, same ingredients were mixed 
depending on the gel concentration changing between 8% to 12%, with the exception 
of using 1.5M Tris-HCl pH 8.8 this time. Wet transfers were done to either PVDF 
membrane or nitrocellulose. 10X transfer buffer for wet transfer, 5X sample loading 
buffer and 10X denaturing reagent (500mM DTT) were also purchased from 
Invitrogen. 
10X SDS Running buffer 144g glycine and 30g Tris were dissolved in 
ddH2O, 50mL 10% SDS was added, and the 
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volume was completed to 1L. Working 
solution is 1X 
10X Transfer buffer 72g glycine and 58g Tris were dissolved in 
ddH2O, 2mL 10% SDS was added, and the 
volume was completed to 1L. Working 
solution is 1X containing 10-20% Methanol 
depending on protein size. 
Blocking solution 5% (w/v) non-fat dry milk was dissolved in 
0.2% TBS-Tween 20, or 5% (w/v) bovine 
serum albumin (BSA) was dissolved in 
0.2% TBS-Tween 20 
10X Tris buffered saline (TBS) 12.9g Trisma base, 87.76g NaCl in 1L of 
ddH2O, working dilution is 1X and pH 8 
TBS-Tween 20 0.2% Tween 20 in 1X TBS 
Ponceau S  0.1% (w/v) Ponceau S and 5% (v/v) acetic 
acid was dissolved in 0.2 % TBS-Tween 20 
Coomassie brilliant blue solution 100mg coomassie brilliant blue G-250, 50ml 
95% ethanol, 100ml 85% phosphoric acid. 
Filtered using whatman paper 
NP-40 lysis buffer 50mM Tris HCl, 150mM NaCl, 1% NP-40, 
0.1% SDS, 1X protease inhibitor cocktail  
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2.2.6 Flow Cytometry Analysis Solutions 
 
Fixative Medium A Fix cells, Invitrogen, GAS003  
Antibody dissolved in PBS-BSA-NaAzide, prepare by adding 
500mg NaAzide and 10g BSA in 1L 1X 
PBS, store at +4  C  
10X Phosphate Buffered Saline (PBS) 80g NaCL, 2g KCl, 14.4g Na2HPO4, 2.4g 
KH2PO4 in 1L ddH2O 
Working dilution is 1X. 
 
 
2.2.7 Single Cell Isolation from Xenograft Tumor Solutions 
 
Dissociation Buffer Prepare DMEM containing 10% FCS and 
dissolve 125U/mL Collagenase type I and 
150U/mL DNase I in it, prepare fresh  
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2.3 METHODS 
 
2.3.1 Tissue Culture Methods 
 
2.3.1.1 Cell lines and growth condition of cells 
 
Hepatocellular carcinoma cell lines used in this study were cultured in either DMEM 
or RPMI media supplemented with 10% fetal calf serum (FCS), 1% non-essential 
amino acids, 100mg/mL penicillin/streptomycin and 1% L-glutamine at 37
0
C and 5% 
CO2. Cell lines Huh-7, Hep40, HepG2, HepG2-2215, Hep3B, Hep3B-TR, PLC, 
Mahlavu, Focus, FLC4, SK-HEP-1 cell lines were cultured in complete DMEM 
medium. Other HCC cell lines Snu-182, Snu-387, Snu-398, Snu-423, Snu-449, and 
Snu-475 were cultured in complete RPMI medium. Cells were passaged into new 
dishes or plates before they reached high confluency in the dish.  
 
2.3.1.2 Passaging the Cells 
 
To passage cells, firstly, the medium was aspirated using sterile glass pipettes and the 
cells were washed at least once with 1X PBS. Then, trypsin-EDTA was added in the 
plate or flask. The amount of trypsin-EDTA was between 0,5- 2ml, depending on the 
surface area of the flask or plate. Trypsinized cells were kept in the incubator for 1-2 
minutes for the detachment of the cells from the surface. Then, detached cells were 
collected in a complete medium using serological pipettes. Cells were mixed by 
pipetting up and down. Desired portion of the collected cells were reseeded on plates 
or flasks depending on the requirements.  
  
27 
 
2.3.1.3 Thawing the Cells 
 
One vial of stock cryovial of interest was taken either from nitrogen tank stocks or 
from – 80 °C freezer stocks and put on ice immediately. The vial was put in the 37 
°C water bath in order to have cell suspension quickly. Cells were resuspended by 
pipetting up and down gently, and transferred into a 15mL falcon tube with several 
milliliters of complete medium. Cells were then centrifuged for 4 minutes at 1500 
rpm. Supernatant containing DMSO was removed and cell pellet was resuspended in 
a complete medium and transferred into plate or flask. Flasks and plates were chosen 
depending on the amount of pellet, smaller flask or dish for less amount of cell pellet. 
Cells were distributed in the flask or dish evenly by moving the flask or the dish 
back-forth and right-left. Cells were kept in incubators, at 37 C and 5% carbon 
dioxide conditions. The day after, cells were washed and unattached cells were 
removed and the mediums were refreshed.  
 
2.3.1.4 Cryopreservation of the Cells 
 
Cell stocks were prepared from the cell in culture with around 60-75% confluency. 
These cells were washed with 1X PBS and trypsinized with appropriate amount of 
trypsin-EDTA. Then, cells were collected with complete medium afterwards in 
15mL falcon tube. Cells were centrifuged for 4 minutes at 1500 rpm. Thereafter, 
freezing medium, containing 10% DMSO and 20% FCS in complete medium, was 
added for resuspending the cells and then, to transfer cell suspension into cryotubes. 
Cryotubes were first kept at -20 °C for about 1 hour. Afterwards, they were stored at 
– 80 °C overnight and transferred into nitrogen tanks. 
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2.3.1.5 Treatment of the Cells 
 
Firstly, cells were seeded in appropriate dishes, flasks or plates according to the 
experiment type. One day after the seeding, the mediums were removed and cells 
were washed either with 1X PBS or serum free media which contains only 0.01% 
FCS depending on the experiment type. Some treatments were done in complete 
DMEM or RPMI mediums. Some treatments are done in serum free medium 
containing 1mM Na2SeO3. And one treatment way is to apply serum free medium 
containing 1mM Na2SeO3 to achieve serum starvation in the environment. Treatment 
mediums containing chemicals, such as Wnt3a or WIF1, etc. was prepared freshly. 
For the control samples, complete mediums containing same amount of solvents 
were prepared, such as water or DMSO. For ODN and microbial byproducts 
treatment, cells were seeded on the first day and on the second day, medium 
containing these elements were added onto the cells. Cells were incubated as long as 
desired. 
 
2.2.1.6 Transient Transfection of Cells with RNAi Max 
 
First of all, siRNA amount to be used should be decided. For this, a trial can take 
place to find the appropriate amount ranging from 10 to 100nM. To transfect the 
cells, HepG2 and HepG2-2215 cell lines can be reverse transfected where cells will 
be seeded while transfection was performed. To do so, in the plate (6-well plate), 
appropriate amount of siRNA is mixed with appropriate amount of RNAi Max in 
OptiMEM medium without any serum and media. Then, this should be incubated for 
10-20 minutes. After that, trypsinized and counted cells were seeded onto the plate. 
Cell number should be about 30-40% confluency. After cell seeding, plate should be 
mixed very well. Depending on your purpose, cells can be examined in 24-72 hours. 
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2.3.2 Total RNA Extraction from Cultured Cells 
 
For RNA extraction from the cultured cells, first of all, cells were collected by 
adding trypsin-EDTA and growth medium. Then, cells were centrifuged and the 
pellets were used for RNA extraction using NucleoSpin RNA II Kit (MN Macherey-
Nagel, Duren, Germany) according to the manufacturer’s protocol.  
 
2.3.3 Immunoperoxidase Staining Assay 
 
For immunoperoxidae staining, first of all, cells or tissues were fixed with 1:1 
acetone:methanol solution for 10 minutes at -20°C. After fixation, cells or tissues 
were washed with 1X PBS. To stop endogenous peroxidase activity, they were 
treated with 3%H2O2 for 10 minutes for cells and 30 minutes for tissues. Then, cells 
or tissues were blocked with 10% fetal calf serum and 0.3% TritonX-100 in PBS. 
They were incubated with primary antibodies for 1 hour in PBS containing 10% fetal 
calf serum and 0.3% TritonX-100 solution. After washing with 1X PBS containing 
0.3% TritonX-100, cells or tissues were incubated for 1 hour with Cytomation 
Envision+Dual link system-HRP (Dako), and eventually the staining was performed 
with DAB detection solution (Dako). Cover slips were then rinsed with distilled 
water and counterstained with haematoxylin (Sigma) for 3-4 min, mounted on glass 
microscopic slides using 90% (v/v) glycerol and examined under light microscope. 
 
2.3.4 Immunofluorescence Staining Assay 
 
For immunofluorescence staining, first of all, cells were fixed with 4% formaldehyde 
for 10 minutes at room temperature, or tissues were fixed with 4% paraformaldehyde 
for 30 minutes at room temperature. After fixation, cell permeabilization was done 
using 0.5% saponin, 0.3% TritonX-100 in 1X PBS solution for 5 minutes, three times 
at room temperature. This step was not needed in immunofluorescence protocol for 
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tissues. Permeabilized cells or tissues were blocked with 10% fetal calf serum (FCS), 
and 0.3% TritonX-100 in 1X PBS for 1 hour at room temperature. After blocking, 
primary antibody incubation was done using a specific antibody prepared in 10% 
fetal calf serum and 0.3% TritonX-100 in 1X PBS for 1 hour at room temperature. 
Primary antibodies were removed and cells were washed with PBS-0.3% TritonX-
100. Then, secondary fluorescent antibodies, anti-rabbit or anti-mouse or anti-goat 
Alexa Fluor 488 or Alexa Fluor 568 were used for the detection of the primary 
antibody. After secondary antibody incubation, cells or tissues were counter stained 
with DAPI (1:10000 dilution in ddH2O) for 1 minute. Finally, cover slips were 
mounted on slides using fluorescent mounting medium and visualized and 
photographed under fluorescence microscope.  
 
2.3.6 Western Blotting 
 
After quantification of the protein concentrations of the samples, equal amounts of 
proteins were used to prepare loading mixtures. 25 to 50µg of proteins were loaded 
into the gel according to the type of experiment. Loading samples were prepared by 
adding 5X Loading buffer, 20X denaturing agent (or 2M DTT), and ddH2O up to the 
final volume of 20 or 30µl per well. Then, prepared loading mixtures were heated at 
100 °C for 10 minutes and chill on ice before loading into the gel. 
In this study, gel concentrations and type of running buffers were chosen mainly 
according to size of the protein of interest. 8%, 10%, and 12% tris-glycine gels were 
the type of gels used. After running, proteins were transferred onto Amersham 
HyBond ECL nitrocellulose or PVDF membranes with wet transfer protocol. 
Transfer buffer was prepared 1X (from 10X stock) with 10% or 20% methanol in 
ddH2O. Before preparation of wet transfer sandwich, all of the materials were soaked 
into transfer buffer, and especially PVDF membranes were extra activated in 
absolute methanol before soaked into transfer buffer. Transfer was done for 90-120 
minutes (longer for proteins with very high kDa) with 100 V voltage applied. During 
the transfer, western blot tank was either kept in cold room or covered with ice.  
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When the transfer was completed, the efficiency of transfer was tested by putting 
membrane into Ponceau S solution for 30 seconds. Then, Ponceau S solution was 
removed by washing membrane in ddH2O for a few minutes. Membranes were 
blocked with 5% non fat dry milk, or 5% BSA in 0.2% TBS-Tween for 1 hour. Short 
time blockings were done at room temperature, whereas over night blockings at +4 
°C. After blocking, primary antibodies were prepared in non fat dry milk solution or 
BSA solutions and incubated for 1-2 hour(s) at room temperature or over night at 
+4°C. After primary antibody incubation, membranes were washed with 0.2% TBS-
T five times for 5, 5, 10, 5, 5 minutes at room temperature. Then, horseradish 
peroxidase conjugated secondary antibodies; anti-mouse, anti-rabbit or anti-goat, 
were used as secondary antibodies according to the type of primary antibody used. 
Secondary antibody incubation was performed at room temperature for 1 hour. After 
this incubation, membranes were again washed five times for 5, 5, 10, 5, 5 minutes at 
room temperature on a shaker. Then, detections were done using chemiluminescent 
detection kit, ECL+ (Amersham, UK) according to the manufacturer’s protocols. 
Finally, X-ray films were exposed to the emitted chemiluminescent light from the 
reaction of horseradish peroxidase and developed in X-ray developer. Time of 
exposure was chosen depending on the detection reagent and the specific antibody 
used against the protein of interest. 
 
2.3.7 Flow Cytometry Analysis 
 
Firstly, treated or untreated cells were trypsinized and they were collected with 
appropriate amount of medium in 15mL falcon tubes. Cells were washed twice with 
1X PBS and they were centrifuged at 1600 rpm for 5 minutes. Then, fixative reagent 
A was added to cell pellets while vortexing samples for 10 seconds. They were 
incubated at room temperature for 15 minutes. Cells were washed with 1X PBS 
containing BSA-NaAzide. Then, cells were incubated with primary antibodies that 
are conjugated with fluorescent dyes, which are diluted in PBS-BSA-NaAzide for 10 
minutes at +4°C. Then, cells were washed twice with PBS-BSA-NaAzide. Finally 
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cells were resuspended in 1X PBS and analyzed using BD CSampler. Antibody 
positivity was assessed depending on the fluorescent intensity of the samples. 
 
2.3.8 Antibody Conjugation 
 
Antibody to be labeled with Atto488, should be 100-200µg in 40-100µL. For each 
10µL of antibody to be labeled, 1-2µL of LL-Modifier reagent should be added, and 
mixed gently. This solution should be added directly onto the Lightning-Link mix 
vial and lyophilized mix should be resuspended with antibody solution. The mix 
should stand 3 hours to overnight incubation at room temperature. After incubation, 
1µL of LL-quencher FD reagent should be added to mix for each 10µL of antibody. 
The conjugate can be used after 30 minutes. The conjugate will be Alexa488 labeled 
and it should be stored at 4°C. 
 
2.3.9 RNA Sample Preparation and Hybridization to Chip 
 
Total RNA isolation from triplicate samples of HepG2 and HepG2-2215 cell lines 
treated with 3 days of serum starvation was performed with Nucleospin RNA kit 
(MN, Düren, Germany) according to the manufacturer’s protocol. RNA quality was 
checked using Agilent Bioanalyzer 2100 kit and software (Agilent Technologies, 
Santa Clara, CA, USA) according to the manufacturer’s protocol. RNA isolates were 
hybridized to Affymetrix HG-U133_Plus2 chips, applying Affymetrix 3’ IVT 
hybridization protocol in Bilkent University Bilgen Affymetrix Center for microarray 
analysis. 
 
2.3.10 Data Analysis of Microarray Samples 
 
Microarray data normalization and class comparison analyzes was performed using 
BRB-Array Tools Version 4.2.1 [66]. Triplicate HEPG2 and HEPG2-2215 samples, 
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which passed the Affymetrix quality control test, were normalized using the RMA 
method. List of >2 fold differentially expressed genes between two classes in 
p<0.001 significance level were identified (2983 genes in total) using the class 
comparison tool of the program. 
Gene set enrichment analyzes (GSEA) were performed using the GSEA desktop 
program version 2.0, downloaded from 
http://www.broadinstitute.org/gsea/downloads.jsp website. Six separate GSEA 
analyzes were performed using C1 to C6 curated gene set lists downloaded from 
molecular signature database (MsigDB) and gene expression data of the >2 fold 
differentially expressed genes of the microarray dataset. Enrichment results of each 
analysis were further studied.  
Table 2.3: List of curated gene sets and their content. 
Gene Set Name Collection 
C1: positional gene sets Gene sets corresponding to each human chromosome 
and each cytogenic band that has at least one gene. 
C2: curated gene sets Gene sets collected from various sources including 
online pathway databases, publications. 
C3: motif gene sets Gene sets that contain that share a cis-regulatory motif 
conserved across the human, mouse, rat and dog 
genomes. 
C4: computational gene sets Gene sets defined by mining large collections of cancer-
oriented microarray data. 
C5: GO gene sets Gene sets are named by GO term and contain genes 
annotated by that term. 
C6: oncogenic signatures Gene sets represent signatures of cellular pathways, often 
dis-regulated in cancer. 
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2.3.11 In vivo Tumorigenicity Assay 
 
HepG2 and HepG2-2215 cells (10 million, each) were suspended in 100µL 1X PBS 
and injected subcutaneously on the back of nude mice; left and right, respectively. 
And animals were examined for palpable tumors on a weekly basis. After palpable 
tumors were observed, tumor measurements were done daily. When tumors reached 
1 mm
3
 volume, the animals were sacrificed and the tumors were taken and were split 
in to four pieces for further analysis. 
 
2.3.12 Single Cell Isolation from Xenograft Tumors 
 
Firstly, the dissociation buffer was prepared freshly. Then, the subcutaneous tumors 
were harvested with help of scissors and forceps. Then, the tumor tissues were 
weighted and appropriate amount of tumor tissues were placed in dissociation buffer. 
For 1g of tumor tissue, 10mL of dissociation buffer was used. In a sterile biosafety 
cabinet, tumor tissues were transferred into petri dishes and minced with razor 
blades. Then tumor cell suspension was titurated through a 5-mL serological pipette 
10 times. Then tumor cell suspension transferred into 50mL falcon tube and vortexed 
for one minute at the highest speed possible. The suspension was incubated at 37  C 
for two hours with vortexing 1 minute every 20 minutes. After the incubation, cell 
suspension was passed through a 40µm strainer and collected in 50mL falcon tube. 
From this point, cell suspension were seeded or directly fixed for further analysis, 
such as flow cytometry. 
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CHAPTER 3 
 
 
RESULTS 
 
3.1 CD133 as a Cancer Stem Cell Marker in Hepatocellular Carcinoma 
 
CD133 (AC133) is a gene encoding a pentaspan transmembrane glycoprotein. This 
protein localizes to membrane protrusions and it is generally expressed in adult stem 
cells. It is thought to function in maintaining stemness. Recently, CD133 expression 
is associated with several cancer types, including brain tumor, epedymoma, prostate 
cancer and hepatocellular carcinoma [34]. Previous studies showed that CD133 
positivity is associated with proliferation, tumorigenicity, chemo- and radio-
resistance [38]. This might be achieved via preferential activation of certain survival 
pathways. Thus, CD133 is a putative marker which is broadly used in identification 
of liver CSCs. In our study, it is the primary marker to label the CSC populations. 
 
3.1.1 Screening of Hepatocellular Carcinoma Cell Lines for CD133 Positivity 
 
After CD133 was decided to use as a marker to identify cancer stem cells in 
hepatocellular carcinoma (HCC), 17 HCC-derived cell lines were screened with 
immunoperoxidase method. These 17 HCC-derived cell lines were Hep3B and 
Hep3B-TR, Huh7, PLC/PRF/5, HepG2 and HepG2-2215, Hep40, FLC4, Sk-Hep-1, 
Focus, Mahlavu, Snu182, Snu387, Snu398, Snu423, Snu449 and Snu475. While 
HepG2, Huh7, Hep3B and Hep40 were identified as well-differentiated cell lines, 
other cell lines were either poorly-differentiated or moderately-differentiated cell line 
[67]. From these 17 cell lines, 6 of them were found to be CD133 positive with 
different frequencies changing from 10 to 98% (Fig 3.1).These 6 cell lines were 
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Hep3B with 80-90% positivity, Hep3B-TR with more than 90% positivity, Huh7 
with 50-70%, PLC with 40-60% and HepG2 with 10-15% positivity and HepG2-
2215 with 70-90% positivity. These frequencies were calculated via qualitative 
observation from immunoperoxidase staining. 
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Figure 3.1: Immunoperoxidase staining of 17 HCC-derived cell lines with CD133 
antibody; photomicrographs were taken under bright field microscope, 40X. Cell 
lines were ranked based on CD133 staining intensities. 
 
3.1.2 Confirmation of Screening Results by Flow Cytometry Analysis 
 
After the first screening of a set of HCC cell lines, CD133 positivity of these cell 
lines were also checked by flow cytometry analysis in order to have quantitative 
results as well as to diminish any error which could be caused in immunoperoxidase 
experiment that is solely depended on qualitative observation. Thus, all 17 cell lines 
were analyzed with flow cytometry using CD133-APC conjugated antibody to detect 
CD133 levels (Fig. 3.2).  
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Figure 3.2: Flow Cytometry analysis of 17 HCC cell lines with CD133-APC 
detection. Cell lines were ranked based on CD133 staining intensities. 
These results were consistent with the immunoperoxidase staining data and they also 
gave us the more accurate percentages of each cell line’s CD133 positivity. After 
these staining methods, cell lines with CD133 positivity were determined according 
to immunoperoxidase and flow cytometry results (Table 3.1). 
Table 3.1: CD133 frequencies of 6 HCC-derived cell lines. 
HCC-derived cell line CD133
+
 (%) by 
Immunoperoxidase 
CD133
+
 (%) by Flow cytometry 
Hep3B-TR 90-99% 90-99% 
Hep3B 80-90% 85-90% 
HepG2-2215 70-90% 75-90% 
Huh7 50-70% 50-70% 
PLC 40-60% 50-60% 
HepG2 10% 10-15% 
 
All over, these results suggest that 6 out of 17 HCC-derived cell lines have CD133 
positive populations which could be cancer stem cells. Thus, characterization of 
these CD133+ subpopulations with further investigation was aimed. 
  
3.2 Effects of Different Signaling Pathways on CD133 Positive Population  
 
After the identification of cell lines that possesses CD133 positivity, effects of 
different signaling pathways were examined. These pathways were chosen because 
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of their roles in embryonic development, liver development, hepatocellular 
carcinogenesis and stem cells [42]. Thus, firstly, Wnt signaling was examined. Wnt 
signaling is a conserved signaling pathway which is linked to hepatocarcinogenesis 
(Appendix A.1). The second signaling pathway to be examined was TGF- pathway 
(Appendix A.2). However, both of these pathways showed a decrease in CD133 
levels. 
 
3.3 Studies on HepG2 Parental Cell Line and Its Clone HepG2-2215 
 
As seen in Appendix A.1 & A.2, investigation of two signaling pathways revealed an 
inverse relationship which was unexpected because of the literature. These findings 
along with two isogenic cell lines with differential CD133 expression prompted us to 
focus on these two cell lines; parental HepG2 and its clone, HepG2-2215 (Appendix 
A.1 & A.2). HepG2 is an adherent cell line which grows in small aggregates, it is 
epithelial-like and from a 15-year-old male. Meanwhile HepG2-2215 is a clone of 
HepG2 which is transfected with four 5'-3' tandem copies of the hepatitis B virus 
(HBV) genome positioned such that two dimers of the genomic DNA are 3'-3' with 
respect to one another. Thus, HepG2-2215, expresses Hepatitis   B e antigen and 
Hepatitis B surface antigen. Immunoperoxidase and flow cytometry analysis showed 
that while HepG2 have 10-15% CD133 positivity, in HepG2-2215 cell line, CD133 
ratio is between 70-90% (Figs. 3.1 & 3.2). 
It was very surprising that while parental cell line has low CD133+ cell population, 
its clone has around 80% positivity. This increase in CD133 levels might be caused 
by HBV infection. However, to be sure that the CD133 positive cell frequency of 
HepG2-2215 is high as 80%, another marker, namely EpCAM, to detect stemness 
more strictly, was used. EpCAM is normally expressed in epithelial cells and it is a 
carcinoma-associated antigen which is widely used in CSC studies. HepG2 and 
HepG2-2215 cell lines were stained with both CD133 and EpCAM markers to detect 
CSCs in a more defined way (Fig. 3.3). 
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Figure 3.3: Detection of CD133
+
 and/or EpCAM
+
 subpopulations in parental 
HepG2 and its derivative HepG2-2212 cell lines by flow cytometry analysis. 
This data showed that while these two cell lines showed no difference in EpCAM 
positivity, HepG2-2215 cell line has significantly more double positive cells which 
supports that this cell line has more cancer stem cells than HepG2 cell line. 
 
3.3.1 Effects of Serum Starvation Model on HepG2 and HepG2-2215 Cell Lines 
 
After this remarkable difference in CD133 positivity between HepG2 and its clone 
HepG2-2215 was found, further studies were performed. Up to this point, all 
experiments were done with serum starvation model. The aim of using serum 
starvation model was to create harsh conditions where normal cancer cells will start 
to die while cancer stem cells will endure these conditions and would remain healthy. 
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This way we could assess if serum starvation was affecting CD133 positivity. The 
cells were seeded on day zero with complete medium and on day 1, they were 
harvested and fixed for FACS analysis. In a parallel plate, cells were first kept under 
complete medium for a day and then, transferred to serum starvation media for 
additional three days (day 4). On day 4, they were fixed and analyzed by flow 
cytometry analysis (Figs 3.4 & 3.5). 
This analysis showed that while serum starvation model did not affect the HepG2-
2215 cell line, this model decreased the CD133 positivity ratio of HepG2 cell line, 
unexpectedly (Fig. 3.4). 
 
 
Figure 3.4: Effects of serum starvation model on CD133 levels of HepG2 and 
HepG2-2215 by flow cytometry analysis. 
To have more accurate results and differentiate real stemness, double staining with 
CD133 and EpCAM were performed to observe effects of serum starvation method 
on CSCs (Fig. 3.5). These data showed that in single staining, CD133
+
 cell frequency 
dropped significantly in HepG2 only (Fig. 3.4). However, double staining revealed 
that HepG2-2215 was also affected from serum starvation with a reduction from 90% 
cells to 80% double positivity (Fig. 3.5). On the other hand, decrease in HepG2 cell 
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line was much more significant. Double positive cell number of HepG2 diminished 
from 10% to 2.5 % (ca. 75% decrease). 
 
 
Figure 3.5: Effects of serum starvation procedure on CD133/EpCAM levels of 
HepG2 and HepG2-2215 by flow cytometry analysis. 
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3.3.2 Efforts to delineate differential expression of CD133 between HepG2 and 
HepG2-2215 
 
After it is found that HCC-derived cell line HepG2 has 10-20% CD133 positivity 
while its clone HepG2-2215 has 70-90% positivity, identifying the reason of this 
difference is the main question. This difference can depend on the fact that the origin 
of the HepG2-2215 clone may be a positive HepG2 cell or this positivity might be 
gained with the HBV transfection and the following consequences. So, the biggest 
question was to find out the reason why HepG2-2215 has higher CD133 positivity 
than HepG2. To address this question, firstly, soluble factors were examined through 
a simple setup. It is hypothesized that any soluble factor that leads to an increase in 
CD133 positivity in HepG2-2215 cell line should be available in its medium and 
HepG2-2215 medium-treated HepG2 should show advanced CD133 positivity. To 
test this, HepG2 cell line was grown in normal complete medium or it was treated 
with either HepG2 medium which was collected from HepG2 cell line after 3 days or 
HepG2-2215 medium which was collected after 3 days (Fig. 3.6). Media were added 
to HepG2 for treatment in serial dilutions (1/1, 1/2 and 1/4) and treatment lasted for 
10 days. This was also conducted for HepG2-2215 cell line to observe effects of 
HepG2 or HepG2-2215 media (Figs. 3.6 & 3.7). 
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Figure 3.6: Possible effects of soluble factors from HepG2 and HepG2-2215 media 
on CD133 levels in HepG2 by flow cytometry analysis. 
 
Figure 3.7: Possible effects of soluble factors from HepG2 and HepG2-2215 media 
on CD133 levels in HepG2-2215 by flow cytometry analysis. 
These findings suggested that CD133 levels of HepG2 and HepG2-2215 were not 
affected by any soluble factor which might be present in media. Thus, it can be 
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concluded that the difference of CD133 positivity of these two cell lines does not 
depend on any soluble factor.  
 
3.3.3 Efforts to Understand the Relatedness of Oval Cells with CSCs 
 
Recent data showed that hepatocytes became oval cells in response to Notch 
signaling activation or injury that provokes a biliary response and then these oval 
cells differentiate into biliary epithelial cells [68]. The mammalian liver is an 
exceptional regenerative organ that following a toxin-mediated injury, exhibits an 
accumulation of atypical ductal cells (ADCs) which are also referred as “oval cells” 
[68]. Oval cells are intra-hepatic stem cells with bi-potentiality and they can give rise 
to two types of epithelial cells in liver; hepatocytes and bile ductular cells [69, 70]. In 
that study, HNF4 was used as a hepatocyte marker while Sox9 was the biliary 
epithelial cell marker. Thus, expression of both of these markers was the sign of oval 
cells with a bi-potential stemness. Oval cells may give rise to CSCs, and possessing 
more oval cells indicates stemness-rich nature. To observe if HepG2 and HepG2-
2215 also express these two markers; HNF4 and Sox9 to validate their stemness, a 
Western blot analysis was performed in HepG2 and HepG2-2215 cell lines that were 
collected from day1 or day4 that was serum-free medium treated (Fig. 3.8).  
 
Figure 3.8: Expression levels of HNF4 and Sox9 in HepG2 and HepG2-2215 cell 
lines by Western blot. 
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From the Western blot analysis, HepG2 and HepG2-2215 cell lines showed that they 
have different amounts of Sox9 expression where HepG2 showed higher expression 
levels. The expression levels of Sox9 in these two cell lines decreased when cells 
were treated with serum starvation model. For HNF4 expression, it seemed like that 
HepG2 had higher levels of HNF4 expression than HepG2-2215, and their 
expression levels also decreased with serum starvation model. Even though, as total 
expression levels, HepG2 expresses both Sox9 and HNF4 in higher amounts, the 
important point was to identify cell number that express both markers in these cell 
lines. To investigate double positive cells, which indicate presence of oval cells, an 
immuno-fluorescence experiment was conducted on HepG2 and HepG2-2215 cell 
lines (Fig. 3.9). 
 
Figure 3.9: Expression levels of HNF4 and Sox9 in HepG2 and HepG2-2215 cell 
lines by Immunofluorescence. Fluorescent microscopy, 40X. 
Immunofluorescence staining data showed that HepG2-2215 cell line had more 
double positive cells for Sox9 and HNF4 than HepG2 cell line. This also implied 
that HepG2-2215 cell line has more cells with bi-potentiality that demonstrated its 
stemness-rich nature. 
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3.4 Effect of CD133
+
 Levels on Tumor Formation Ability 
 
Since HepG2-2215 cell line showed higher levels of CD133 and EpCAM positive 
subpopulation and more double positive cells for Sox9 and HNF4, CSC 
subpopulation in HepG2-2215 was bigger than HepG2. Thus, HepG2-2215 should be 
able to form a bigger tumor than HepG2 cell line. Also, it was expected that when 
injected to a mice, HepG2-2215 cell line would show a more rapid tumor growth 
than HepG2 cells. To investigate this, a tumorigenicity assay was conducted on 5 
male, atymic, nude mice where HepG2 cells were injected to the left side of the mice 
while HepG2-2215 cells were injected to right side. After injections, first tumor 
growth was observed at day 15 post injection and then, tumor growth kinetics were 
observed (Figs. 3.10).  
50 
 
 
Figure 3.10: A) Tumor growth kinetics of HepG2 and HepG2-2215 cell lines. (Bold 
lines, left side/HepG2; dashed lines, right side/HepG2-2215). B) Comparison of 
tumor volumes of HepG2 or HepG2-2215 derived tumors on day 23 and day 46. C) 
Average tumor weights of tumors derived from HepG2 or HepG2-2215. 
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Palpable tumors were observed at day 15 after injection and from that point; tumors 
were measured three times a week (Fig. 3.10). When the tumor volumes have 
reached more than 1000 mm
3
, animals were sacrificed and tumors were collected. 
Their weights were also measured to see if the volume and the weight were 
consistent with each other or not (Fig. 3.10.C).Tumor photos were shown in Figure 
3.15. In 4 out of 5 mice, right side tumor was bigger than left side.  
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Figure 3.11: The representative photos of tumors that were collected from xenograft 
nude mice. 
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Tumorigenicity assay showed that HepG2-2215 cell line has higher tumor formation 
ability than HepG2 cell line as expected. HepG2-2215-derived tumors were observed 
earlier than HepG2 (Fig. 3.10.A). Moreover, their volumes were also higher than 
HepG2-derived tumors (Fig. 3.10.B). Another observation from this experiment was 
that the appearances of tumors were significantly different from each other. While 
tumors derived from HepG2 cells showed darker color implying more blood vessels 
in the tumor environment, HepG2-2215-derived tumors showed lighter color and 
they appeared to have more lipids in the tumor environment (Fig. 3.11). 
  
3.4.1 Flow Cytometry Analysis of Xenograft Tumor Tissues 
 
In tumorigenicity assay, after tumors were taken, they were split into four equal 
pieces for further studies. Firstly, cells were dissociated to obtain single cell 
suspension and then, these cells were stained with CD133-APC to observe their 
CD133 positivity levels (Fig. 3.12). 
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Figure 3.12: Differential CD133
+
 levels of HepG2- and HepG2-2215-derived 
tumors. 
This analysis showed that while HepG2-derived tumor cells had 5-7% CD133 
positivity, HepG2-2215-derived tumor cells had 30-40% CD133 positivity (Fig. 
3.12). This supported the view of the HepG2-2215 cell line has more cancer stem 
cells which resulted in more rapid tumor growth in xenograft study.  
After it has been shown that HepG2-2215 cell line had more CD133 positivity even 
after xenograft study, these tumor masses were further investigated with 
CD133/EpCAM staining with flow cytometry to detect CSCs more accurately with 
two markers (Fig. 3.13). Also, to characterize tumor microenvironment, M1/M2 
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macrophages were also checked by flow cytometry using CD86 for M1 macrophage 
marker and CD206 for M2 macrophage marker (Appendix Fig. A3.5).  
 
Figure 3.13: Differential CD133/EpCAM levels of HepG2- and HepG2-2215-
derived tumors. 
These data suggested that even after xenograft studies, HepG2-2215 continued to 
have higher double positive cell ratio for CD133 and EpCAM than HepG2 cell line. 
This implied that HepG2-2215-derived tumors have more cancer stem cells which 
cause more rapid tumor initiation and these cells also might help the maintenance of 
the tumor. 
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3.5 Microarray Study between HepG2 and HepG2-2215 Cell Lines 
 
To have a better understanding of what caused the higher levels of CSCs in HepG2-
2215 cell line, a microarray study between HepG2 and HepG2-2215 cell lines was 
conducted from triplicate samples (Fig. 3.14). Then, genes with at least 1.5 fold 
changes in expression took into consideration for further studies. 
 
Figure 3.14: Representative heatmap of microarray analysis between HepG2 and 
HepG2-2215 cell lines. 
Microarray analysis revealed that 4486 genes were expressed differentially, while 
1926 of them were up-regulated in HepG2-2215 cell line.  
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2983 differentially expressed genes with more than 2 fold change and p< 0.001 
significance value between HepG2 and HepG2-2215 cell lines were analyzed with 
GSEA (Gene Set Enrichment Analysis) method. C1, C2, C3, C4, C5, and C6 curated 
gene set lists were separately analyzed (Table 2.3 & 3.3).  
Table 3.3: List of gene numbers that were enriched in either HepG2 or HepG2-2215 
in curated gene set lists. 
Cell line 
with 
enrichment 
C1 (330) C2 (4555) C3 (826) C4 (837) C5 (1363) C6 (189) 
HepG2-
2215 
140 2770 516 463 819 113 
HepG2 163 1785 310 374 544 76 
 
In order to simplify the complex GSEA results for easier interpretation enrichment 
pathway maps were generated based on lists of enriched genes in each gene sets 
using the Cytoscape pathway generation program with Gökhan Yıldız (personal 
communication). The pathways were generated for each curated gene set lists. Gene 
sets in the pathways and genes causing pathway interactions in the gene sets were 
further investigated using the data of the maps of the each pathway. Gene sets were 
categorized in four groups for further analyzes; development/differentiation, 
signaling, stem cell, and virus/HCC/cancer. 73 gene sets in total were determined 
using this method (Appendix Table A4.1, A4.2, A4.3 & A4.4). With the help of these 
data, more meaningful results were obtained that led to a focus on FGFR signaling 
pathway. 
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3.5.3 FGFR Signaling Pathway 
 
After microarray analysis, it has been shown that FGFR signaling pathway was 
significantly up-regulated in HepG2 cell line. All four FGF receptors, FGFR1, 
FGFR2, FGFR3 and FGFR4 were down-regulated in HepG2-2215 cell line (Table 
3.4). In addition to the receptors, FGFR signaling ligand FGF2 were also down-
regulated in HepG2-2215 cell line. 
Table 3.4: Differentially expressed FGFR signaling pathway.  
Gene Symbol Probe set ID Fold change (HepG2-
2215/HepG2) 
Fold change 
(HepG2/HepG2-2215) 
FGF13 205110_s_at 122,3173 0,0082 
FGFR3 204379_s_at 0,611131 1,64 
FGFR1 211535_s_at 0,407627 2,45 
FGFR4 204579_s_at 0,398808 2,51 
FGFR2 203638_s_at 0,208346 4,8 
FGF2 204422_s_at 0,085947 11,63 
 
Differential expression of FGFR signaling pathway genes were studied with Western 
blot technique using P-FGFR antibody, which recognizes phosphorylated FGF 
pathway receptors including FGFR1, FGFR2, FGFR3 and FGFR4 (Figs. 3.15 & 
3.16). Firstly, both HepG2 and HepG2-2215 cell lines were analyzed for their 
phosphorylated FGFR levels with Western blot technique (Fig. 3.15). 
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Figure 3.15: Expression levels of P-FGFR in HepG2 and HepG2-2215 cell lines by 
Western blot analysis. 
Because serum starvation model was used in most of the analysis, protein of HepG2 
and HepG2-2215 cell lines that were collected from day1 (untreated) and day4 
(serum starvation treated). And Western blot analysis was repeated for these samples 
(Fig. 3.16). 
 
Figure 3.16: Expression levels of P-FGFR in HepG2 and HepG2-2215 cell lines by 
Western blot analysis. 
These findings showed that HepG2 cell line indeed has higher levels of P-FGFR than 
HepG2-2214, and as expected P-FGFR levels decreased in both cell lines upon 
serum starvation treatment. However, this decrease more significantly in HepG2-
2215 cell line which makes a bigger difference in P-FGFR levels in these two cell 
lines (Fig. 3.16). 
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3.5.3.1 Inhibition of FGFR Pathway 
 
HepG2 cell line has low levels of CD133+ cells and its FGFR signaling is up-
regulated while HepG2-2215 has high levels of CD133+ cells and FGFR signaling is 
down-regulated. This differential expression of CD133 and FGFR signaling pathway 
genes might affect each other in a reverse fashion. To investigate the relationship 
between FGFR signaling pathway and CSCs, HepG2 and HepG2-2215 cell lines 
were treated with SU5402 which is a potent FGFR inhibitor. Two different 
concentrations of SU5402 (2µM and 10µM) were used for 48 hours treatment. After 
the treatment, cells were collected and fixed for flow cytometry analysis (Fig. 3.17 & 
3.18). Cells were stained with CD133-APC, EpCAM-FITC and FGFR2 antibody that 
is conjugated to Alexa488 with Lightning-Link kit (Fig. 3.17 & 3.18). 
 
Figure 3.17: Effects of inhibition of FGFR signaling pathway via SU5402 treatment 
for 48 hours on CD133/EpCAM levels in HepG2 by flow cytometry. 
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Figure 3.18: Effects of inhibition of FGFR signaling pathway via SU5402 treatment 
for 48 hours on CD133/EpCAM levels in HepG2-2215 by flow cytometry. 
These results showed that inhibition of FGFR signaling via SU5402 treatment 
decreased FGFR levels in both HepG2 and HepG2-2215 in dose-dependent manner. 
However, this decrease in FGFR levels was affected CD133/EpCAM levels in only 
HepG2 cell line, while HepG2-2215 showed inconsistency in its CD133/EpCAM 
levels with increasing SU5402 dose (Fig. 3.17 & 3.18). Unfortunately, in HepG2, 
CD133/EpCAM levels dropped with decreasing FGFR levels, which is unexpected 
(Fig. 3.17). 
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3.5.3.2 siRNA Knockdown of FGFR2 
 
After FGFR inhibition via SU5402, this time, FGFR signaling pathway was inhibited 
by siRNA knockdown of FGFR2. For this, a pool of siRNAs targeting FGFR2 was 
used in different concentrations ranging from 12.5nM to 100nM in 2X dilutions. 
Cells were reverse transfected and after 72 hours treatment, cells were collected for 
flow cytometry (Fig. 3.19 & 3.20). Again, CD133, EpCAM and FGFR2 levels were 
checked.  
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Figure 3.19: Effects of inhibition of FGFR signaling pathway via siRNA treatment 
against FGFR2 on for 72 hours CD133/EpCAM levels in HepG2 by flow cytometry. 
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Figure 3.20: Effects of inhibition of FGFR signaling pathway via siRNA treatment 
against FGFR2 for 72 hours on CD133/EpCAM levels in HepG2-2215 by flow 
cytometry. 
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These results showed that in HepG2 cell line, there was a decrease in FGFR2 levels 
with siRNA treatment in a dose-dependent manner. However, this was not observed 
in HepG2-2215 cell line. In HepG2 cell line, it is observed that with decreasing 
levels of FGFR2, CD133/EpCAM levels showed a slight increase (Fig. 3.19). 
CD133/EpCAM levels in HepG2-2215 demonstrated inconsistent up and downs 
upon siRNA treatment (Fig. 3.20). 
 
3.6 Effects of Suppressive ODN on CD133 Frequency of HepG2 and 
HepG2-2215 
  
Suppressive ODN (A151) is known to suppress the DNA-driven immunostilmulation 
and it has been already studied in inflammation related oncogenesis. Since 
inflammation and cancer growth is closely related, role of inflammation in cancer 
stem cells is a very important question. Also, another ongoing study showed that 
suppressive ODN can repress fibrosis which is generally an important step in 
hepatocarcinogenesis and it also decreases stemness (Aydin, M. et al., unpublished 
data). To address this, both HepG2 and HepG2-2215 cell lines were treated for one 
day with high dose (3µM) and low dose (0.5µM) A151, suppressive ODN, and as a 
control D35 flip was used which does not promote any immune stimulatory or 
inhibitory effect (Fig. 3.21 & 3.22).  
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Figure 3.21: Effects of suppressive ODN (A151) on CD133/EpCAM levels in 
HepG2. 
 
Figure 3.22: Effects of suppressive ODN (A151) on CD133/EpCAM levels in 
HepG2-2215. 
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These findings suggested that in both HepG2 and HepG2-2215, suppressive ODN 
treatment decreased CD133/EPCAM levels. However, this one day treatment should 
be further investigated with longer exposure time and replenishment every day.  
Since, suppressive ODN repress DNA-driven immunostimulaton and HepG2-2215 is 
a cell line that can produce HBV particles because it was transfected with four 
tandem copies of HBV, these findings suggested that the role of HBV infection 
should be further investigated to reveal the relationship between HBV and CSC 
formation. The differential levels of CD133/EpCAM positivity between HEpG2 and 
HepG2-2215 might be explained via HBV transfection. 
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CHAPTER 4 
 
 
DISCUSSION 
 
This study primarily focused on the identification of cancer stem cell populations in 
HCC-derived cell lines. Using a putative CSC marker in HCC, CD133, these 
subpopulations were investigated under the effects of different signaling pathways. 
Also, focus on two cell lines, one parental and one HBV-infected daughter cell line, 
possible explanations for the increase in CD133
+
 cell number, were studied  
 
4.1. Identification of Cancer Stem Cells in HCC-derived Cell Lines 
 
After it was shown that many solid tumors, including HCC have cancer stem cells in 
their tumor bulk that can initiate and maintain the tumor tissue, for the treatment of 
tumors, targeting CSCs was drawn into the attention [71] To target CSCs, the first 
aim was to identify and characterize these cells. In HCC, there were many markers to 
identify CSCs which were associated with either tumorigenicity, or self-renewal, or 
multipotency [36]. Some of these markers were CD90, CD133, EpCAM, CD44, 
CD24, CD13, OV6 and so on. However, from all these possible markers, CD90, 
CD133 and EpCAM were highlighted ones for CSC identification in HCC [34]. 
 Thus, first we aimed to do an initial screen in the panel of 15 HCC-derived cell lines 
with CD133 to find the frequencies of each cell line’s CD133 positivity. Previous 
studies have shown that different human liver cell lines have different frequencies of 
CD133
+
 cells and these cells posses a greater colony forming efficiency and higher 
proliferation rate along with greater ability to form tumor in vivo [37]. From this 
initial screen, we found 6 out of 17 cell lines have CD133
+
 cells as subpopulation. 
Their CD133 positivity frequencies were changing from 8% to 98% as expected 
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from previous studies. The next step was to examine effects of different signaling 
pathways on CSC populations. 
 
4.2 Effects of Wnt Signaling Pathway on CD133
+
 Cell Population 
 
Wnt/-catenin signaling pathway is a highly conserved pathway that plays a crucial 
role in embryonic development, growth, survival, regeneration and self-renewal [48]. 
Apart from these roles, this pathway is associated with hepatic fate specification, 
prenatal liver development, and liver organogenesis [43]. Finally, it is known that in 
one third HCC patients, aberrant Wnt activation is observed [46]. These numerous 
factors led us to investigate possible role of Wnt/-catenin signaling pathway in CSC 
regulation. For this initial experiment, we chose a cell line with moderate CD133 
positivity, Huh7. This cell line was also broadly used for cancer stem cell studies. 
Huh7 cells were treated with Wnt/-catenin pathway activator, Wnt3a, and inhibitor, 
WIF-1 in order to examine any increase or decrease in the frequency of CD133 
positivity. From our findings, CD133+ cells ratio in Huh7 cell line did not change 
with WIF-1 treatment. Moreover, activation of Wnt/-catenin signaling pathway via 
Wnt3a treatment decreased this ratio significantly.  
Unfortunately, previous data suggested that elevated levels of Wnt and its 
downstream mediators were found in CD133
+
 HCC cells [41]. Also, it has been 
shown that Wnt/-catenin signaling is associated with activation of tumorigenic liver 
progenitor cells [72]. However, these studies showed different aspects of link 
between Wnt/-catenin signaling and CSCs. First of all, we didn’t check for the basal 
Wnt levels which might be too high that it was saturated. This can explain why 
further activation of Wnt had negative effects on CD133
+
 cell numbers. On the other 
hand, WIF-1 is Wnt inhibitory factor 1 which binds to Wnt ligands to prevent their 
bindings to Frizzled and LRP5/6. Thus, any constitutively active Wnt pathway 
cannot be inhibited via this way. That might explain why WIF-1 didn’t change 
CD133 levels. Moreover, even though it is known that Wnt/-catenin pathway is 
associated with activation of tumorigenic liver progenitor cells, this effect was never 
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studied on CD133
+
 cells. So, for Huh7 cell line, Wnt/-catenin signaling pathway 
activation may have reverse effects on CD133 positivity which leads to decrease in 
positivity rate.  
 
4.3 Effects of TGF- Signaling Pathway on CD133+ Cell Population 
 
TGF- signaling pathway is a complex pathway that consists of many members and 
regulates many cellular functions [49]. This signaling pathway has a crucial role in 
cell cycle regulation, immune system, apoptosis, and embryonic development and so 
on. TGF- signaling pathway has a rather complex role during HCC development. 
Initially, at an early stage of HCC, TGF- pathway inhibits oncogenesis via inducing 
apoptosis, and in some HCCs, it has been shown to suppress tumor formation with 
autophagy activation [47]. However, dysregulated TGF- signaling is associated 
with hepatocarcinogenesis [51].  
Meanwhile in our initial screen of 17 HCC-derived cell lines, two cell lines came 
forward because of their high CD133
+
 cell ratio. This cell line is Hep3B and it has 
90% frequency for CD133 positivity. On important fact about this HCC-derived cell 
line is that this parental cell line was treated with TGF-1 in stepwise manner to 
generate a cell line which is TGF--resistant. This daughter cell line is Hep3B-TR 
with more than 90% CD133 positivity.  
These facts pointed out that investigation of effects of TGF- signaling pathway on 
CD133
+
 cells in Hep3B might be a perfect candidate to move on. We used Hep3B-
TR cell line as a negative control since it is resistant to TGF-. To activate TGF- 
signaling, TGF-1 was used while inhibition was achieved through anti-TGF-1 
treatment. As a result, it was found out that inhibition of TGF-b signaling did not 
change CD133
+
 cell ratio while activation of TGF-b decreased this ratio in Hep3B 
cell line. And as expected, Hep3B-TR cell line was not affected from both of these 
treatments.  
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This might be an expected results overall, when the dual role of TGF- was 
considered in HCC. Also, it has been shown that lack of responsiveness to TGF- led 
to the generation of CSCs [41]. This result also supports the hypothesis that the 
interrupted TGF- signaling pathways might result in HCC because of disruption of 
a normal pattern of cellular differentiation by hepatic progenitor/stem cells [73, 74]. 
On the other hand, this result conflicts with a previous study that claims TGF- is 
capable of up-regulating CD133 expression in Huh7 cell line in a time- and dose-
dependent manner [75]. However, because this study was performed with Huh7 cell 
line, it is very normal to obtain different results from a different HCC-derived cell 
line. 
 
4.4 Studies on HepG2 and HepG2-2215 Cell Lines  
 
After these findings, two isogenic cell lines with differential CD133 levels were 
investigated .Parental HepG2 cell line has the lowest CD133 positivity rate, around 
10%, while its clone that is transfected with hepatitis B virus, namely HepG2-2215 
has 70-90% CD133
+
 cell population. Normally, HepG2 is HCC-derived cell line 
from 15-year-old male, and HepG-2215 is transfected with four 5'-3' tandem copies 
of the hepatitis B virus (HBV) genome, and can express Hepatitis B e antigen and 
Hepatitis B surface antigen. Initial results showed that parental HepG2 cell line has 
around 10-20% CD133
+
 cells while its clone HepG2-2215 has 70-90% CD133
+
 cells. 
Because using single marker for CSC identification is insufficient, we decided to 
include another marker in our studies to identify CSCs in a more accurate way. This 
second marker was EpCAM that is associated with invasiveness, self-renewal and 
tumor formation, and it is widely used in CSC studies in HCC [36]. Then, these two 
cell lines were analyzed with flow cytometry for double staining of CD133 and 
EpCAM. As expected, while HepG2 has around 15% double positive cells, HepG2-
2215 cell line has more than 75% double positive cells which supports that HepG2-
2215 cell line has a higher ratio of cancer stem cells in its population.  
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One important point we did throughout the experiments was to use serum starvation 
model to generate harsh conditions where tumor cells will die while cancer stem cells 
will endure the conditions and thus, their subpopulation will enhance. To test if this 
hypothesis is true or not, experiments comparing serum free medium treated and 
untreated HepG2 and HepG2-2215 cell lines were analyzed. The first analysis was 
performed with CD133 staining. And it reveals that serum starvation model did not 
affect CD133
+
 cell frequency in HepG2-2215 cell line. However, the CD133
+
 cell 
frequency in HepG2 dropped from 20-25% to 10-15%. This might be explained by 
the notion that not all CD133 positive cells are cancer stem cells. Thus, only true 
cancer stem cells kept their status during serum starvation model and the other tumor 
cells that are CD133 positive died during the treatment in HepG2 cell line. To test 
this, double staining for EpCAM and CD133 was performed in these two cell lines. 
We observed a decrease in both HepG2 and HepG2-2215 cell lines. Double 
positivity frequency decreased from around 90% to 80-75% in HepG2-2215 cell line 
whereas the decrease in HepG2 was more significantly, dropping from around 10-
15% to 2-3%. This might support the idea of not all labeled cells were true CSCs or 
these results might be the indicator of serum starvation model was not the best idea 
to enhance CSC population since it affected all the cells without discriminating CSCs 
from tumor cells.  
After these studies, the reason underlying the difference of these two cell lines in the 
number cancer stem cell population was studied. Firstly, to eliminate any soluble 
factors, which may cause this CSC population difference, these cell lines were 
treated with their own media as well as each other’s. The results showed that 
treatment of HepG2 with HepG2 or HepG2-2215 medium did not affect CD133
+
 cell 
number and HepG2-2215 was not affected by these treatments as well. 
After we could not find any soluble factors that might affect CD133 positivity in 
these two cell lines, a recent finding caught our attention. It has been shown that 
activation of Notch dependent cascade or an injury that provokes biliary response 
causes hepatocytes to go under cellular reprogramming to become an oval cell which 
will give rise to biliary epithelial cells [68]. In this article, HNF4 was used as 
hepatocyte marker while Sox9 as biliary epithelial cell marker. Transition from 
hepatocytes to oval cells and then, to biliary epithelial cells were demonstrated with 
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double staining of cells with these two markers and cells expressing both of these 
markers were counted as oval cells that have multipotency to give rise to both 
hepatocytes and biliary epithelial cells [69]. From this starting point, these markers 
were used to identify oval cell in these cell lines to assess stemness. Initial data 
showed that HepG2 has higher levels of HNF4 and Sox9 and these levels decrease 
upon serum starvation treatment. However, double staining of these cell lines showed 
that HepG2-2215 has more double positive cells than HepG2, which supports that 
HepG2-2215 has a stemness-rich nature with a higher CSC population. 
All these data, up to this point, supported that HepG2-2215 cell line has more cells 
with cancer stem cell’s features. Since, cancer stem cells are associated with tumor 
initiation and growth, testing the tumorigenicity potential of these two cell lines was 
the next step [41]. As expected, HepG2-2215 cell line showed a higher tumor 
formation and growth rate than HepG2 cell line. After tumorigenicity assay, excised 
tumor tissues were further investigated for CD133 and EpCAM staining. These data 
showed that HepG2-2215 has higher CD133
+
 cell ratio than HepG2, even though 
cells were injected to a mice and then, single cells were harbored from excised tissue. 
This was same for the double positive cell numbers as well. So, this analysis showed 
that HepG2-2215 has higher tumorigenicity potential and after the tumor formation, 
tumor tissue from HepG2-2215 still has higher number of CD133 and EpCAM 
positive cells. 
 
4.5 Microarray Study between HeppG2 and HepG2-2215 Cell Lines 
 
To reveal the underlying reasons for the difference in CSC number of these cell lines, 
a microarray analysis were performed for HepG2 and HepG2-2215 cell lines. 
Analysis of microarray gave us too many genes and signaling pathways, which these 
genes are associated with. However, FGFR signaling pathway caught our attention 
because of many members of this signaling pathway was found to be differentially 
expressed in these two cell lines. Thus, firstly, FGFR levels of these cell lines were 
studied. Even though, with serum starvation, FGFR levels dropped, still, HepG2 has 
significantly higher levels of FGFR than HepG2-2215. These findings suggested that 
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there might be a inverse proportion between FGFR levels and CSC formation. Thus, 
activation of FGFR signaling pathway may alter CD133 and EpCAM positive cell 
numbers in these cell lines. This hypothesis is also supported by the study which 
showed that reduction in FGFR2IIIb isoform was associated with more aggressive 
growth of HCC [55]. The aggressiveness of a tumor might be explained by CSC-
richness which also supports the reverse relationship between CSCs and FGFR 
signaling pathway. 
Investigation of FGFR signaling via SU5402, which is a potent FGFR inhibitor or 
siRNA knockdown of FGFR2 were performed to observe the relationship between 
FGFR levels and CD133/EpCAM positive cell ratios. Initial trials of SU5402 
treatment experiments showed a decrease in FGFR2 levels in a dose-dependent 
manner in both HepG2 and HepG2-2215. However, changes in CD133/EpCAM 
levels showed no consistency in dose dependent-manner in HepG2-2215 cell line. 
This might be caused because of very low, basal FGFR levels in HepG2-2215. 
Meanwhile CD133/EpCAM levels in HepG2 showed a decrease upon SU5402 
treatment which was contrary to our hypothesis, surprisingly.  
In siRNA treatments, HepG2 cell lines showed a decrease in FGFR levels in dose 
dependent-manner and luckily, there was a slight increase in its CD133/EpCAM 
levels, which is not significant. On the other hand, HepG2-2215 showed inconsistent 
results in both FGFR and CD133/EpCAM levels which remained unexplained. 
Unfortunately, because of limited time, these experiments could not be repeated. So, 
the relationship between FGFR signaling and CSCs should be further studied. 
Finally, in cancer progression, immune system plays a crucial role. And suppressive 
ODN (A151), which has been already known with its suppressive role in 
immunostimulation, was studied in cancer types because of its anti-inflammatory 
effects. A recent data showed that suppressive ODN can repress fibrosis which is 
generally previous step of HCC and also down-regulates stem cells (Aydin, M. et al., 
unpublished data). To test if suppressive ODN, A151, has negative effects on CSC 
population, HepG2 and HepG2-2215 cell lines were treat with A151. Results showed 
that A151 decreased the CD133/EpCAM double positive ratio in both HepG2 and 
HepG2-2215 cells. These exciting results pointed out that the close relationship 
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between immunity and cancer progression. However, these findings should be 
further investigated for longer durations and daily replenishments of ODNs for more 
accurate data. 
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CHAPTER 5 
 
 
FUTURE PERSPECTIVES 
 
Microarray analysis between HepG2 and HepG2-2215 cell lines revealed that FGFR 
signaling might play a role in HCC CSC formation. Experiments targeting FGFR 
signaling should be repeated for optimization. Optimal doses for both SU5402 to 
inhibit FGFR pathway and siRNA to knockdown FGFR2 should be found. To 
confirm these doses, Western blot analysis along with flow cytometry for FGFR2 
could be performed. Beside from inhibition, effects of activated FGFR pathway 
should be investigated via FGFR signaling pathway ligand.  
Since, suppressive ODN showed a decrease in CD133/EpCAM positive cell ratios, 
effects of A151 should be further investigated by administrating the suppressive 
ODN to cells with longer exposure and daily replenishment. If decrease in the ratios 
persists, then, more immune-related aspects of hepatocarcinogenesis could be studied 
to find the effects of immune system on CSCs.  
One important aspect of CSCs is that they are chemo- and radio-resistant. To test 
this, both of these cell lines should be injected to atymic nude mice, again. However, 
this time, when tumors reached a certain volume, an effective treatment for cancer 
should be applied to mice in order to see the resistance of these cell lines. Even, 
HepG2-2215 showed higher tumor formation ability, it is also important that it 
should also show resistance to treatments. If this cell line is also resistant, then, 
further studies to find underlying mechanisms of CSCs in HCC can be studied. 
Moreover, tumorigenicity assay should be repeated with more animals. This time, 
each cell should be injected to independent animals to avoid any effects that may 
arise from injecting both cell lines to the same animal. Also, different cell numbers 
should be injected to mice to see the lowest cell amount to be injected to generate a 
tumor. Tumorigenicity assay should be performed for a longer duration. 
77 
 
Also, in the case of finding a specific signaling pathway or elements that might be 
responsible from CSC formation in HCC, such as FGFR pathway or A151, effects of 
this pathway or these elements should be studied with tumorigenicity assay, and 
then, the treatment of formed tumors. With this in vivo approach, it can be examined 
that if found pathway or elements were really linked to CSCs or not. Also, this 
pathway or these elements may affect only tumor growth or resistance to treatment 
which will suggest new treatment ways. 
Finally, this work was performed on the cell lines rather than primary cell cultures. 
When it is considered, it is obvious that cell lines were passaged too many times, and 
they were studied for many years which may cause differentiation of these cell lines. 
Thus, the results of this study may not represent the reality in normal tumor 
microenvironment. To reveal more realistic results, after finding a significant result, 
these experiments should be studied on primary tumor cell lines. Or, fresh tissues 
directly taken from patients can be investigated.  
To sum up, in HCC, formation of CSCs is still unknown and more studies should be 
done to find the therapeutic approaches to target them or to prevent their formation in 
the first place. 
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APPENDIX 
 
APPENDIX A 
 
Appendix A1. Negative Effects of Wnt Pathway Activation 
 
Wnt/-catenin signaling pathway regulates stem cell pluripotency and cell fate 
decisions during development via cross-talking with other pathways, such as retinoic 
acid, TGF-, FGF and BMP [44]. It has been known that this signaling has a role in 
liver development while aberrant Wnt signaling has also been linked to HCC [43]. 
Thus, in order to study effects of Wnt signaling on cancer stem cells in HCC, in one 
of the CD133 positive cell lines, Wnt pathway was activated by its ligand Wnt-3a 
and inhibited by WIF-1. For this experiment, Huh7 cell line was chosen because of 
its moderate CD133 positivity (Fig. A1.1). Also, cells were seeded in low density to 
observe colony formations. In Wnt signaling, the pathway is activated via binding of 
a Wnt ligand, like Wnt-3a. This reagent was directly added to the medium of the 
cells as the inhibitor WIF-1, which inhibits the signaling by binding to the ligand and 
preventing its activation ability.  
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Figure A1.1: Differential Effect of Wnt-signaling pathway in response to activator 
or inhibitor treatment on CD133 expression levels of Huh7 via immunoperoxidase 
procedure. Bright field microscope, 40X. 
 
After the immunoperoxidase staining, with the help of a bright field microscopy, 
formed colonies with more than 50 cells were counted and their CD133 positivity 
assessed as higher than 80%, lower than 20% or in between. Then, these countings 
were statistically analyzed and Student’s t-test was performed (Fig. A1.2). From 
these staining trials, it has been shown that while WIF-1 treatment did not change 
CD133 frequency of Huh7 cell line, Wnt-3a treatment showed a decrease in the 
positivity. And statistical analysis, namely Student’s t test confirmed these findings. 
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Figure A1.2: Differential Effect of Wnt-signaling pathway in response to activator 
or inhibitor treatment on CD133 expression levels of Huh7 (p<0.05, NS=not 
significant).  
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Appendix A2. Negative Effects of TGF- Pathway Activation 
 
After it has been found that Wnt pathway activation is decreasing the CD133 
positivity in Huh7 cell line (Fig. A1.2), other pathways’ effects were examined. In 
the set of 17 HCC-derived cell lines, there were two cell lines with the highest 
CD133
+
 ratios. These cell lines were Hep3B, which is epithelial, liver cell line taken 
from an 8-year-old juvenile, and its isogenic cell line, Hep3B-TR, which is a Hep3B-
derived cell line that rendered a resistance to TGF- by stepwise exposure to TGF-
1. And Hep3B cell line has CD133 positivity frequency between 80- 90%, while 
Hep3B-TR cell line has more than 90% CD133 positivity. Thus, these two cell lines 
were a great chance to study the effects of TGF- signaling pathway that controls 
proliferation, cellular differentiation and other functions [50]. Another important 
point about TGF- is that the activation of this signal cascade is closely related to 
fibrosis, liver cirrhosis and subsequent HCC development [52].  
The effects of TGF- signaling pathway were examined through the treatment of 
these cell lines with a TGF- pathway activator and inhibitor (Fig. A2.3). The 
activator was TGF-1 while the inhibitor was anti-TGF-1 antibody. Because it has 
been already known that Hep3B-TR is a cell line resistant to TGF- signaling, the 
aim of using that cell line was to have a negative control. After the treatment, these 
two cell lines were analyzed with immunoperoxidase and flow cytometry for CD133 
positivity (Figs. A2.3 & A2.4). 
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Figure A2.3: Effects of TGF- signaling pathway in response to activator and 
inhibitor on CD133 levels of Hep3B and Hep3B-TR cell lines by immunoperoxidase. 
Bright field microscopy, 40X. 
 
Figure A2.4: Effects of TGF-b signaling pathway on CD133+ cell frequency in 
Hep3B and Hep3B-TR cell lines by flow cytometry analysis in panel A. Data was 
statistically analyzed with Student’s t test, p<0.01, panel B. 
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These findings showed that activation of TGF- signaling pathway has negatively 
affected CD133
+
 HCC subpopulation in Hep3B cell line. However, inhibition of 
TGF-b pathway did not affect CSC population. As expected, Hep3B-TR cell line was 
acted as negative control and didn’t show any changes in both treatments that 
activated and inhibited TGF- pathway. 
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Appendix A3. Flow Cytometry Analysis of Xenograft Tumor Tissues 
 
Figure A3.5: Detection of M1/M2 macrophage levels of HepG2- and HepG2-2215-
derived tumor samples by flow cytometry analysis. 
After tumors were taken from nude mice that were injected with HepG2 cells to their 
left sides and HepG2-2215 to their right sides, these cells were dissociated to obtain 
single cell suspension. Cells were stained for M1 (CD86 as a marker) and M2 
(CD206 as a marker) markers to study tumor microenvironment. However, there was 
no consistent result and these results showed that in these tumors’ 
microenvironments, M1 and M2 levels were very low. 
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Appendix A4. Gene Set Enrichment Analysis of Microarray Study 
 
Table A4.1: Differentially expressed gene sets belonging to development or 
differentiation category. 
Gene Set Enriched in sample Transcription factor 
V$HNF4ALPHA_Q6 HepG2 HNF4A 
V$HNF6_Q6 HepG2 HNF6A 
V$HOXA3_01 HepG2 HOXA3 
 
Table A4.2: Differentially expressed gene sets belonging to stem cells  category. 
Gene Set Enriched in 
sample 
MIKKELSEN_PLURIPOTENT_STATE_DN HepG2-2215 
ZHOU_PANCREATIC_ENDOCRINE_PROGENITOR HepG2-2215 
RPS14_DN.V1_UP HepG2-2215 
BOQUEST_STEM_CELL_UP HepG2 
HOFMANN_MYELODYSPLASTIC_SYNDROM_LOW_RISK_UP HepG2 
INGRAM_SHH_TARGETS_DN HepG2 
PARK_OSTEOBLAST_DIFFERENTIATION_BY_PHENYLAMIL_UP HepG2 
REACTOME_REGULATION_OF_KIT_SIGNALING HepG2 
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BMI1_DN.V1_DN HepG2 
BMI1_DN_MEL18_DN.V1_DN HepG2 
Table A4.3: Differentially expressed gene sets belonging to signaling pathways 
category. 
Gene Set Sub-category Enriched in 
Sample 
BIOCARTA_INTEGRIN_PATHWAY Cell-cell junction 
signaling 
HepG2 
PID_SYNDECAN_4_PATHWAY Cell-cell junction 
signaling 
HepG2 
PID_NECTIN_PATHWAY Cell-cell junction 
signaling 
HepG2 
PID_EPHA_FWDPATHWAY Cell-cell junction 
signaling 
HepG2 
PID_FAK_PATHWAY Cell-cell junction 
signaling 
HepG2 
PID_AVB3_INTEGRIN_PATHWAY Cell-cell junction 
signaling 
HepG2 
REACTOME_CELL_CELL_JUNCTION_ORGANIZA
TION 
Cell-cell junction 
signaling 
HepG2 
REACTOME-CELL_CELL_COMMUNICATION Cell-cell junction 
signaling 
HepG2 
REACTOME_PECAM1_INTERACTIONS Cell-cell junction 
signaling 
HepG2 
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REACTOME_ADHERENS_JUNCTIONS_INTERAC
TIONS 
Cell-cell junction 
signaling 
HepG2 
REACTOME_DOWNSTREAM_SIGNALING_OF_A
CTIVATED_FGFR 
FGFR signaling HepG2 
REACTOME_NEGATIVE_REGULATION_OF_FGF
R_SIGNALING 
FGFR signaling HepG2 
REACTOME_SIGNALING_BY_FGFR FGFR signaling HepG2 
REACTOME_SIGNALING_BY_FGFR_IN_DISEASE FGFR signaling HepG2 
REACTOME_FGFR4_LIGAND_BINDING_AND_AC
TIVATION 
FGFR signaling HepG2 
REACTOME_FRS2_MEDIATED_CASCADE FGFR signaling HepG2 
KEGG_INSULIN_RECEPTOR_SIGNALLING_PATH
WAY 
Insulin signaling HepG2 
REACTOME_INSULIN_RECEPTOR_SIGNALING_
CASCADE 
Insulin signaling HepG2 
REACTOME_SIGNALING_BY_INSULIN_RECEPT
OR 
Insulin signaling HepG2 
KRAS_DF.V1_UP Ras signaling HepG2-2215 
KRASKIDNEY_UP.V1_UP Ras signaling HepG2-2215 
KRAS_SO_UP.V1_UP Ras signaling HepG2-2215 
KARAKAS_TGFB1_SIGNALING TGF-beta 
signaling 
HepG2-2215 
TGFB_UP.V1_DN TGF-beta 
signaling 
HepG2 
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Table A4.4: Differentially expressed gene sets belonging to viral infection, HCC or 
cancer category. 
Gene Set Enriched in sample 
PHONG_TNF_TARGETS_UP HepG2-2215 
V$AP4_Q5 HepG2-2215 
V$AP4_Q6_01 HepG2-2215 
V$EFC_Q6 HepG2-2215 
V$ICSBP_Q6 HepG2-2215 
V$IRF_Q6 HepG2-2215 
TTAYRTAA_V$E4BP4_01 HepG2-2215 
CERVERA_SDHB_TARGETS_2 HepG2 
SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM1 HepG2 
V$CEBPGAMMA_Q6 HepG2 
V$RFX1_02 HepG2 
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Appendix A5. Effects of Suppressive ODN Treatment on CD133 Levels 
 
 
Figure A5.6: Effects of suppressive ODN (A151) treatment on CD133/EpCAM levels 
of HepG2 and HepG2-2215 cell lines by flow cytometry analysis. 
